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A principal cause of sensorineural hearing loss is injury to or loss of cochlear hair
cells, which are critical components of sound transduction. These auditory hair
cells do not naturally regenerate in mammals. Loss of hair cells often leads to a
degeneration of the processes that innervate them along with the ganglion cell
bodies of the auditory nerve. The only currently accepted treatment for hearing
loss of this type is the cochlear implant, an auditory prosthesis that has been in
clinical use for over 30 years. While the cochlear implant has been successful in
providing or restoring hearing to over 100,000 patients, there are limitations to
the hearing provided by the implant, particularly for complex sounds such as
speech in noise and music. The peripheral processes and ganglion cell bodies
receive and process the electrical stimulation from the implant, and thus the
survival of these components of the auditory nerve is critical to the perception of
sound from the cochlear implant. This dissertation presents two novel methods of
promoting auditory nerve survival and regrowth following hair cell loss. The first
method used an adenoviral construct containing a gene insert for brain – derived
neurotrophic factor, designed to increase endogenous production of this growth
factor. The introduction of this adenovirus into the cochlea led to a decrease in
electrophysiological and psychophysical thresholds to cochlear implant
stimulation and promoted long – term ganglion cell survival. This study was
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unique in addressing the psychophysical effects of the anatomical changes
induced by growth factor treatment. In the second method, a specialized implant
coating was designed to attract growth of peripheral processes to make contact
with a cochlear implant in vivo. In this study, a new histological technique was
developed, which allowed visualization of peripheral processes and evaluation of
their spatial relationship with an implant. This coating attracted significant
neuronal growth in close proximity to the implant and decreased the impedance
between implant electrodes. These studies together demonstrate the significant
plasticity of the auditory nerve to survive following deafness, and indicate the




Hearing loss is a major medical concern that typically presents in one of
two forms. Conductive hearing loss is generally a problem with amplification, and
the source of the hearing loss is in the middle ear or the outer ear. This type of
hearing loss can usually be remedied by surgery or with a hearing aid, which is
worn externally and enhances sound waves so they will reach the inner ear for
normal neuronal processing. Sensorineural hearing loss (SNHL) occurs at the
level of the inner ear, the auditory nerve, or higher levels of auditory system and
is not easily remedied. When sound waves enter the inner ear, they vibrate the
basilar membrane, to which cochlear hair cells are attached. These hair cells
transduce the mechanical energy of sound waves into neural impulses and send
temporal and frequency information via peripheral nerve fibers, to the primary
ganglion cells of the auditory nerve, spiral ganglion cells (SGCs), located in the
modiolus. The SGCs then send out central processes that form the auditory
portion of the VIII cranial nerve, the vestibulocochlear nerve. Fig. 1.1
demonstrates the anatomy of the inner ear. In many cases of SNHL, the cochlear
hair cells are missing or damaged and acoustic hearing is non – functional.
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Auditory hair cells do not naturally regenerate in mammals, thus this form of
hearing loss is permanent and irreversible.
The cochlear implant (CI) offers a viable and effective treatment option for
those with severe to profound SNHL where hair cells are lost but some functional
auditory nerve still exists. This prosthesis is an electrode array that is placed in
one of the fluid – filled spaces of the cochlea and electrically stimulates the
remaining auditory nerve. This implant bypasses the function of the cochlear hair
cells by providing direct electrical energy to the SGCs. This stimulation can
provide hearing to those who have never heard before, and restore hearing to
those who have lost it. The CI functions well in quiet environments, but most
users have trouble understanding complex sounds such as speech with
background noise and music (Wilson et al., 2003; McDermott, 2004). Both
clinical and basic research endeavors are underway with the goal of providing CI
users with a more complete auditory experience. There are several CI models
available, and the design of both the implant and the sound processor software
has been greatly enhanced in the past several decades since the first implant
(Rubinstein and Miller, 1999). In addition to implant engineering, several lines of
research are aimed at improving the cochlear environment so that it is more
receptive to electrical stimulation from the implant.
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Fig. 1.1: Mid – modiolar section of guinea pig cochlea
A cross – sectional image of the guinea pig cochlea is shown to demonstrate the
inner ear anatomy. The organ of Corti (OC), which contains cochlear hair cells, is
located in the scala media (SM).  This is one of the fluid – filled spaces of the
cochlea, along with the scala vestibuli (SV) and the scala tympani (ST). Hair cells
send out auditory nerve peripheral fibers (P) to ganglion cell bodies (GC). The
cochlear implant (CI), indicated by the dashed circle, is placed in the ST,
although exact lateral placement in vivo is variable. Scale bar = 100µm.
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In humans, cochlear hair cell loss can be caused by a variety of genetic
and environmental factors. Animal models of SNHL are similar to human
pathologies and hair cell loss and nerve degeneration is typically induced by over
– exposure to noise or ototoxic drugs. Aminoglycosides such as neomycin and
kanamycin can destroy hair cells and the organ of Corti if applied either directly
within the cochlea or given systemically (Prosen et al., 1978; Robertson and
Johnstone, 1979; Kim and Raphael, 2007). The combination of an
aminoglycoside and a loop diuretic, such as ethacrynic acid, given systemically,
has also been proven effective at destroying hair cells and initiating neural
degeneration bilaterally (West et al., 1973; Xu et al., 1993).
When inner hair cells are lost or damaged, a secondary and progressive
degeneration of the peripheral processes, SGCs, and eventually the central
auditory nerve often occurs (Spoendlin, 1975; Webster and Webster, 1981;
Jyung et al., 1989). This degeneration could be due to a lack of electrical and
chemical stimulation from the hair cells, as activity from both the peripheral and
central sources is needed to maintain the integrity of SGCs. The level of
degeneration is influential in the success of cochlear implantation, as the nerve
needs to be viable and receptive to electrical stimulation. Fortunately, although
hair cells do not naturally regenerate, both the peripheral processes and SGCs
can be regenerated. A number of studies have shown that growth factor
intervention following hair cells loss can slow or attenuate the loss of the auditory
nerve (Staecker et al., 1996; Miller et al., 1997; Ylikoski et al., 1998; Marzella and
Gillespie, 2002; Miller et al., 2002; Roehm and Hansen, 2005).
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Perhaps the most effective and most studied growth factors that influence
cochlear morphology are brain – derived neurotrophic factor (BDNF) and
neurotrophic factor – 3 (NT – 3). Both BDNF and NT – 3 are members of the
neurotrophin family of neurotrophic factors, and both are necessary for the
normal development and innervation of the cochlea (Staecker et al., 1996;
Pirvola et al., 1997; Fritzsch et al., 1999). These growth factors and their high
affinity receptors, TrkC and TrkB, are present in longitudinal gradients in the
developing cochlea. There is a high concentration of BDNF and TrkB in the
apical end of the cochlea, with decreasing expression in the basal end. NT – 3
and TrkC has an opposite expression pattern in the young cochlea, with the
highest concentration in the base (Fritzsch et al., 1997; Fritzsch et al., 1999).
Despite this developmental difference, both BDNF and NT – 3 are effective at
promoting SGC survival in both young and mature tissue (Staecker et al., 1995;
Hartnick et al., 1996; Staecker et al., 1996; Miller et al., 1997). This effect can be
seen if there is a delay in introducing growth factors to the deafferented nerve
(Gillespie et al., 2004; Yamagata et al., 2004), but it is possible that the pro –
survival effects of growth factor treatments cease when treatment ceases
(Gillespie et al., 2003; Shepherd et al., 2008). Both NT – 3 and BDNF have been
shown to promote peripheral processes growth after hair cell loss, in vivo and in
vitro (Malgrange et al., 1996; Staecker et al., 1996; Cho et al., 1998; Wise et al.,
2005).
While the effects of growth factors on cochlear morphology have been
studied in some depth, the typical manner of introducing growth factors into the
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cochlea in animal models is not clinically feasible. Most in vivo studies use single
injections or an osmotic pump to deliver drugs to the inner ear. A single injection
of growth factors at the time of cochlear implant surgery is feasible, but does not
provide lasting benefits. While the osmotic pump can provide sustained release
of drugs and is more effective at introducing drugs to the cochlea than a bolus
injection (Brown et al., 1993; Prieskorn and Miller, 2000), it cannot be maintained
long – term. The pump has an implanted finite reservoir of drugs, which requires
surgery to replace. This creates an unacceptable level of infection risk and
inconvenience for human use. A more permanent solution is needed to make
growth factor intervention a relevant method to aid CI users.
The direct clinical relevance of CI research naturally dictates a systems
level analysis, as any changes in cochlear morphology are only beneficial if the
function of the CI is affected. The perception of sound from the CI should
therefore be assessed physiologically or psychophysically. In this dissertation,
the effects of two novel methods of introducing growth factors to the cochlea
were determined using electrically – evoked auditory brainstem responses
(EABRs) and psychophysical detection thresholds. The psychophysical paradigm
has been developed over several decades and is well – established (Miller et al.,
1995; Su et al., 2008). This paradigm is a simple go/no – go, positive
reinforcement task that determines an animal’s awake processing of electrical
stimulation from the CI, and is further explained in Chapter 2.
The EABR is a staple in auditory system and CI performance assessment.
Acoustically – evoked ABRs are commonplace in evaluating human hearing
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levels, which makes this test particularly relevant in animal models of CI
performance. The EABR is an evoked potential recording in response to CI
stimulation, and is used as a general indicator of the status and functionality of
the auditory pathway (Hall, 1990). Animals are typically deafened prior to EABR
recordings to eliminate hair cells and any effect they may have on hearing levels
(Brownell et al., 1985; Miller et al., 2006) and more accurately mimic the clinical
stimulation of CI users. An example of a typical EABR waveform is presented in
Fig. 1.2.
There are four peaks in the EABR waveform, which represent ascending
regions of the auditory systems. Wave I is the response from the auditory nerve,
Wave II is the response from the cochlear nucleus, Wave III is thought to arise
from the superior olivary complex, and Wave IV is thought to arise from the
inferior colliculus. Although Wave I may be the best indicator of the function of
the cochlear nerve, this peak is often obscured by stimulus artifact. Wave II is
therefore the first and most often analyzed peak, and changes in the amplitude of
this peak are directly related to changes in stimulus intensity. Wave II amplitude
decreases as stimulus intensity decreases and EABR thresholds are defined as
the lowest current level at which Wave II is noticeably different from background
noise, and typically have an predetermined amplitude (van den Honert and
Stypulkowski, 1986; Miller et al., 1995). EABR thresholds to CI implant
stimulation provide a routine, quantifiable, although coarse, test of the status of
the auditory pathway.
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Fig. 1.2: Typical EABR response waveform.
The source of stimulation was from the intrascalar cochlear implant and
responses can be recorded from either subdermal needle electrodes or screws
placed within the skull. Each peak, labeled I – IV, represents a response from an
ascending region of the auditory pathway, and Wave II is typically followed to
determine EABR thresholds and changes in EABRs over time. Peak amplitude
decreases with decreasing current level. From (Miller et al., 1995).
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This dissertation presents two novel methods that were designed to
gradually introduce growth factors to the cochlea, sustain growth factor
expression over time, and improve physiological and/or psychophysical response
to CI stimulation. The first method used an adenoviral construct to up – regulate
the internal production of BDNF. A number of viral vectors, including
adenoviruses, have been adapted for use in biological systems and modified so
that they do not induce substantial rejection, immune response, or over –
proliferation (Raphael et al., 1996; Weiss et al., 1997; Stover et al., 1999;
Ishimoto et al., 2002). This viral technique is therefore a potential way of
changing gene expression and providing a source of growth factors to the
degenerating cochlea. These growth factors are internally produced and
therefore less susceptible to degradation and could provide a longer duration of
protection than exogenous proteins. The virus used here, labeled Ad.BDNF, was
a replication – deficient recombinant virus with a gene insert for BDNF that was
first used to promote survival of retinal ganglion cells following axotomy (Di Polo
et al., 1998). It has also been shown to promote SGC survival following hair cell
loss (Nakaizumi et al., 2004; Rejali et al., 2007). The current study was designed
to test the effects of Ad.BDNF on long – term survival of SGCs in conjunction
with a cochlear implant. This method and the results of this study are presented
in Chapter 2, “Over – expression of BDNF by adenovirus with concurrent
electrical stimulation improves cochlear implant thresholds and survival of
auditory neurons”.
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The second method used a conducting polymer and hydrogel coating on
the cochlear implant to release growth factors into the cochlea. Conducting
polymers have been developed in a number of engineering fields and have
recently gained usage in the biomedical field (Green et al., 2008; Hendricks et
al., 2008). When deposited around electrodes, the polymer creates a “fuzzy”
coating which dramatically increases the surface area of the electrode (Yang et
al., 2007). This improves charge transport and helps preserve the fidelity of the
signal in stimulating electrodes and improves signal – to – noise ratio in recording
electrodes (Cui et al., 2003; Ludwig et al., 2006). Conducting polymers can
provide both controlled and sustained drug release, as drugs can be incorporated
into the polymer and released through electrical stimulation. Hydrogels are also
common in the biomedical field and are clinically used to aid in tissue formation
and wound healing (Zimmermann et al., 2000). Hydrogels form an imitation
extracellular matrix that supports tissue, skin, bone, and nerve growth and
regeneration. Hydrogels are mostly water – based structures, with lightly linked
polymer chains, which allow some drugs to be absorbed and diffused (Coviello et
al., 2006; Mano et al., 2007). The combination of hydrogel and conducting
polymer has not only the potential to aid in the long – term distribution of growth
factors to the cochlea, but also increase the biocompatibility of the implant and
facilitate electrical stimulus transmission. This method is investigated in Chapter
4, “Cochlear implant hydrogel coating promotes auditory nerve fiber growth within
the scala tympani in direct vicinity of implant” and Chapter 5, “The effect of
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PEDOT on cochlear implants electrophysiological thresholds and impedances in
vivo”.
Chapter 3, “Visualization of spiral ganglion neurites within the scala
tympani with a cochlear implant in situ”, presents a histological method that was
developed over the course of this dissertation in response to a need to visualize
the spatial relationship between the cochlear implant and nerve regrowth. This
method was designed to aid the studies in Chapter 4 and 5, but could be
applicable to several lines of auditory nerve regeneration research.
The studies described in this dissertation include multi – level analyses of
a research topic that has significant clinical applicability. Novel techniques were
developed and expanded which led to intriguing results that encourage further
study. These projects provide an indication of the comprehensive effects of
auditory nerve regeneration and survival on cochlear implant function.
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Chapter 2
Over – expression of BDNF by adenovirus with concurrent electrical
stimulation improves cochlear implant thresholds and survival of auditory
neurons
2.1. Introduction
The most accepted treatment for sensorineural hearing loss (SNHL) at the
level of the inner ear is the cochlear implant (CI), a neural prosthesis that
electrically stimulates the auditory nerve and replaces the actions of lost hair
cells and cochlear mechanisms. Current CIs provide a lower quality of hearing
than acoustic hearing, especially for complex sounds such as music and speech
in noisy background. One variable known to affect the perception of sound with a
CI is the condition of the surviving auditory nerve (Pfingst et al., 1981; Pfingst
and Sutton, 1983; Colombo and Parkins, 1987; Shepherd and Javel, 1997). In
animal models of SNHL, degeneration of the spiral ganglion cells (SGCs), the
primary neurons of the auditory pathway, often follows hair cell loss (Spoendlin,
1975; Webster and Webster, 1981; Leake and Hradek, 1988).
Trophic support of SGCs may be provided by electrical stimulation from
the cochlear implant. Many studies that show an effect of electrical stimulation
use chronic or continuous levels of electrical stimulation (several hours/day,
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every day of the week for several weeks or months) (Miller, 2001). There is,
however, evidence that lower levels of electrical stimulation, such as that used in
psychophysical or electrophysiological testing, can promote SGC survival,
especially when that stimulation is initiated within a week of deafening (Hartshorn
et al., 1991; Miller and Altschuler, 1995; Mitchell et al., 1997). The combination of
electrical stimulation with growth factor treatment has also been shown to be
more effective than either treatment alone in promoting SGC survival (Hegarty et
al., 1997; Kanzaki et al., 2002; Shepherd et al., 2005). Importantly, the post –
deafening treatment of growth factors and electrical stimulation can improve the
physiological response to cochlear implant stimulation (Shinohara et al., 2002;
Shepherd et al., 2005).
Both in vivo and in vitro work indicate a number of growth factors can
promote SGC survival, including brain – derived neurotrophic factor (BDNF)
(Hartnick et al., 1996; Staecker et al., 1996; Miller et al., 1997; Shinohara et al.,
2002; Gillespie et al., 2003; Nakaizumi et al., 2004), neurotrophin – 3 (NT – 3)
(Staecker et al., 1995; Staecker et al., 1996; Farinas et al., 2001; Bowers et al.,
2002), glial cell line – derived neurotrophic factor (Ylikoski et al., 1998; Altschuler
et al., 1999; Yagi et al., 2000; Kanzaki et al., 2002) and ciliary – derived
neurotrophic factor (Staecker et al., 1995; Hartnick et al., 1996). BDNF and NT –
3 have also been shown to induce regrowth of auditory nerve peripheral
processes (Malgrange et al., 1996; Staecker et al., 1996; Wise et al., 2005). Both
BDNF and NT – 3 are necessary for normal inner ear development, and there
appears to be a longitudinal gradient of these proteins in the developing cochlea
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such that NT – 3 is more robust in the basal end of the cochlea and BDNF more
robust in the apex of the cochlea (Fritzsch et al., 1999). Knockout mice lacking
the NT – 3 protein show an incomplete development of the basal region of the
cochlea, and BDNF – deficient mice show an incomplete development of the
apical portion of the cochlea (Fritzsch et al., 1997; Fritzsch et al., 1997; Farinas
et al., 2001). These data suggest auditory nerve survival in the basal region of
the cochlea may be most influenced by NT – 3. However, there is some evidence
that the longitudinal gradients and actions of NT – 3, BDNF, and their high –
affinity receptors in the cochlea may reverse over time (Adamson et al., 2002;
Schimmang et al., 2003). The ability of either growth factor to promote neuronal
survival may therefore vary considerably from developing to adult tissue, and
both NT – 3 and BDNF are currently considered effective options for mature
auditory nerve survival treatments.
In animal models of SNHL, the most common method of introducing
growth factors into the deafened cochleae is through osmotic pumps, which allow
a short – term (weeks) but continuous release of the chosen growth factor. While
the continuous supply of drugs has advantages over a bolus injection, these
pumps are susceptible to a number of problems, including degradation of
exogenous proteins at body temperature, potential infection from changing the
pump, and cannula clogging. It is possible that this exogenous growth factor
treatment may need to be constantly maintained in order to preserve any benefit
to SGC survival (Gillespie et al., 2003). Gene therapy may help overcome these
issues by instigating a continuous supply of fresh and locally made growth
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factors. The morphology of the cochlea makes it a good candidate for gene
therapy and previous work using viral vectors to up – regulate growth factors in
the cochlea has shown transgene expression in the mesothelial cells that line the
scala tympani (Yagi et al., 2000). This effect has been seen throughout the
length of the cochlea (Raphael et al., 1996; Stover et al., 1999; Nakaizumi et al.,
2004), indicating that even when the efficacy of gene expression decreases with
distance from the base, the secreted growth factor may reach and influence more
apical regions.
An adenoviral construct containing a BDNF gene insert (Ad.BDNF) has
been previously characterized both in vivo and in vitro (Di Polo et al., 1998;
Nakaizumi et al., 2004; Rejali et al., 2007). Di Polo et al. (1998) showed the
effect of this viral construct on the survival of retinal ganglion cells following
axotomy, where transgene expression of Ad.BDNF was seen in Müller glial cells
along with enhanced survival of retinal ganglion cells. This study was the first to
provide in vivo evidence that Ad.BDNF – transfected cells secrete bioactive
BDNF. Rejali et al. (2007) more recently showed that Ad.BDNF transfected
guinea pig fibroblast cells could release bioactive BDNF in vitro. The introduction
of Ad.BDNF into the cochlea following aminoglycoside deafening has been
shown to enhance SGC survival at both 28 days (Nakaizumi et al., 2004) and 48
days (Rejali et al., 2007) post – inoculation. However, no research to date has
addressed the impact of Ad.BDNF treatment on functional measures. In the
current study, we introduced Ad.BDNF to the aminoglycoside – damaged
cochlea of guinea pigs, and assessed psychophysical and electrophysiological
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detection thresholds to cochlear implant stimulation. Data collected over 80 days
showed that the combination of adenoviral – mediated growth factor up –
regulation and the non – continuous electrical stimulation used for threshold
testing resulted in improved auditory nerve survival and that this survival was
associated with lower (better) functional thresholds.
2.2. Methods
Overview
Following operant conditioning with acoustic stimuli, animals were
unilaterally ototoxically deafened, inoculated with one of two adenoviral
constructs (Ad.BDNF or Ad.Empty), and implanted with a multichannel cochlear
implant. Following implantation, psychophysical and electrophysiological
thresholds were measured for 80 days. Animals were then euthanized and both
cochleae prepared for histological analysis. A separate group of animals was




Eight pigmented male guinea pigs (Elm Hill, Chelmsford, Mass, USA)
were used in the first part of this study, four animals in an experimental group
and four animals in a control group. Animals began psychophysical training with
a free – feeding schedule until their weights reached 400 g, at which time a
restricted diet was instituted. This restricted diet was designed to keep animals at
80 % of free – feeding weight, encourage performance in a food – reward based
psychophysical task, and maintain good health. Animal weights at the time of
inoculation and implantation ranged from 780 to 1200 g. Pure tone auditory
brainstem response thresholds verified normal hearing in all tested animals prior
to being placed in one of the treatment groups.
Adenoviral vectors
Animals received one of two adenoviral constructs. Animals in the
experimental group received an adenoviral vector with a mouse BDNF gene
insert, driven by the cytomegalovirus promoter, labeled as Ad.BDNF, as
previously described (Di Polo et al., 1998). Control animals received an
adenoviral construct containing no gene insert, labeled as Ad.Empty (a gift from
GenVec, Inc., Gaithersburg, MD, USA).
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Deafening
All animals were unilaterally deafened in the left ear via an aminoglycoside
antibiotic (neomycin) introduced directly into the cochlea. For general anesthesia
animals were given a ketamine (40 mg/kg) and xylazine (10 mg/kg) mix (IM and
kept warm using a heating blanket. Lidocaine was used as a local anesthetic,
and an incision was made in an arc caudal to the pinna of the left ear. The
underlying muscle and tissue were gently pushed back to reveal the bulla and a
small hole was made in the bulla with the tip of a scalpel blade. The round
window was punctured and some perilymph was absorbed. Neomycin (10 %
neomycin sulfate in sterile water, 60 !L) was slowly infused into the scala
tympani via the round window using a 100 !L glass syringe and a 30 G needle.
Following neomycin infusion, the hole in the bulla was sealed with carboxylate
cement and the incision in the skin was stitched in layers. Although other
methods of aminoglycoside deafening are effective (West et al., 1973; Xu et al.,
1993), direct infusion of neomycin into the perilymph was chosen as the ototoxic
method in this study to ensure a within – subject control, as this technique does
not deafen the contralateral ear. There is a small possibility that contralateral hair
cells may degenerate with this paradigm due to fluid leakage through the
cochlear aqueduct. Contralateral ears were examined post – mortem to confirm
that this did not occur. Ototoxic deafening of only one ear also allows the option
to implant the contralateral ear and continue behavioral experiments should the
implant fail. Neomycin in volumes as low as 10 !L has been shown to not only
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eliminate hair cells, but also create a flat, uniform epithelium from the organ of
Corti within 4 days of injection into the perilymph (Kim and Raphael, 2007).
Inoculation and implantation
All animals were unilaterally implanted in the deafened left ear. Four days
after neomycin deafening, animals were given general and local anesthesia as
detailed above, and an incision was made down the midline of the head. Muscle
and connective tissue were gently pushed apart to reveal the skull. Six screws
were placed in the skull; three for electrically – evoked auditory brainstem
response recordings and three screws formed a triangle around bregma and held
the head of a restraining bolt, which held a cochlear implant in place. A thin coat
of acrylic was applied to these screws to aid in securing the restraining bolt. The
incision from the deafening procedure was then reopened and the carboxylate
cement removed. For treated animals, a single injection of 5 !L Ad.BDNF
(approximately 4x1012 adenoviral particles/mL) was placed through the round
window into the perilymph of the basal turn of the scala tympani via a bent tip 30
G needle and a 10 !L glass syringe. In control animals, 5 !L of Ad.Empty was
administered in a similar manner. Animals were left undisturbed for 20 min to
allow permeation of the adenoviral solution. A small cochleostomy was then
made apical to the round window to expose the scala tympani, and a
multichannel cochlear implant was placed into the scala tympani. All animals
received an 8 – electrode implant, which resembled the apical end of the Nucleus
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CI – 22™ human implant and was manufactured by Cochlear Corporation
(Nucleus Ltd., Lane Cove, Australia). The implants had an approximate center –
to – center distance between electrodes of 0.75 mm, which allowed 5–6
electrodes to be inserted into the cochlea. Post – mortem evaluations of implant
position revealed an insertion depth range of 2.25 – 5.90 mm, an average of 4.27
± 1.09 mm, and no differences between experimental and control groups
(Student’s t – test p = 0.63). Only six of the eight implant electrodes were
stimulated, and were labeled A through F where A was the most apical. All
electrodes were within the basal turn of the cochlea. The letter G was used to
identify an extracochlear ground electrode, which was placed in the post –
auricular muscle. See Fig. 2.1 for details on the implant dimensions and labeling
system.
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Fig. 2.1: Diagram of multichannel implant and electrode configurations.
The banded electrodes are labeled A through F, where A is at the most apical
(first inserted) end of the implant. MP = monopolar stimulation where the return
electrode was a ground wire placed in the post – auricular muscle. BP = bipolar
stimulation where the return electrode was immediately adjacent to the
stimulating electrode. TP = tripolar stimulation where the two electrodes
surrounding the stimulating electrode were return electrodes. All stimulation
configurations are placed on arbitrary electrodes for illustration purposes.
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Psychophysical assessment
Animals were trained in a go/no – go positive reinforcement auditory
stimulus detection task, similar to that described (Prosen et al., 1978; Miller et al.,
1995; Su et al., 2008). Briefly, animals were placed in a wire cage inside a sound
– attenuating chamber and trained to respond to acoustic stimuli (including both
pulse trains and sinusoids) by releasing a button. A food reward was given for
correct responses. The method of constant stimuli was used to vary sound
pressure levels, and threshold was defined as the level at which correct releases
occurred on 50 % of the trials. An animal was considered trained when 10
consecutive thresholds were within a range of ± 5 dB SPL.
The day after implantation, animals began testing with the same paradigm
as described above, but with electrical stimulation from the cochlear implant.
Animals were tested for thresholds to cochlear implant stimulation in one 90 min
session per day, 5 days/week, for 11 weeks. In our psychophysical detection
paradigm, it can take up to 40 days for animals to obtain stable thresholds to
electrical stimulation. We continued our experiment for double this time (80 days)
in order to obtain enough threshold values in each electrode configuration for
valid statistical tests. Testing began with the apical monopolar electrode
configuration (labeled B–G, see Fig. 2.1), which was tested until a threshold was
obtained. Thresholds for each remaining configuration were then obtained on a
random schedule for the remainder of the testing period. Six electrode location
and configuration combinations were tested on each of the animals used in the
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study. These electrode combinations consisted of apical and basal end of the
implant tripolar configurations (electrodes A–B–C and C–D–E), apical and basal
bipolar configurations (A–B and D–E), and apical and basal monopolar (B–G and
D–G) configurations. The electrical stimulus for psychophysical testing was a
train of 100 Hz sinusoid bursts (200 ms on, 100 ms off), generated by a
Tucker–Davis Technologies (TDT) digital signal processor. The stimuli were sent
to a TDT programmable attenuator, then to a controlled – current stimulator and
finally to the animal’s implant. To monitor any changes in implant status,
electrode impedances were measured daily using a 1 !A rms, 1 kHz sinusoidal
stimulus.
EABR
Electrically – evoked auditory brainstem responses (EABRs) were
recorded under general anesthesia every two weeks, beginning one week post –
implantation. Electrical stimuli were generated by a TDT digital processor, sent to
a programmable attenuator, fed to a controlled – current stimulator, and delivered
to the implant through a percutaneous connector mounted on the animal’s skull.
Neural activity was recorded using alligator clips attached to screws that were
placed in the skull 2 cm anterior to bregma, 1 cm lateral of bregma on the
implanted side, and 1 cm posterior to bregma. A bipolar and monopolar electrode
configuration was tested at both apical and basal locations on the implant, giving
four stimulating electrode pairs (A–B, B–G, D–E, and D–G, see Fig. 2.1). Stimuli
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were 50 !s phase duration monophasic alternating polarity square pulses. EABR
threshold was defined as the lowest level at which there was a repeatable Wave
II, as agreed upon by two unbiased observers.
Histology
Eighty days post – implantation, the animals were deeply anesthetized
and perfused intracardially with 2 % glutaraldehyde and both cochleae were
removed. Tissue processing was completed as previously described (Yagi et al.,
2000) modified as described below. Each cochlea was locally perfused with 2 %
glutaraldehyde and placed in 3 % EDTA solution to decalcify until sufficiently soft
for sectioning (approximately 1 month). Once decalcified, the implant was
removed from the left ear, and each cochlea was embedded in JB – 4 resin and
sectioned in the mid – modiolar plane, which provided 6 measurable profiles of
Rosenthal’s canal (Kanzaki et al., 2002). Sections were 3 !m thick, and every
third section was kept and stained with 1 % toluidine blue in 1 % sodium borate.
These sections were evenly divided into a caudal, middle and rostral group and
one slide from each of these groups was chosen by a random number generator
for evaluation. Each profile of Rosenthal’s canal in each of these three slides was
evaluated by an observer who was blinded to the treatment groups, using SPOT
Imaging™ software for data acquisition and MetaMorph Offline™ software for
data analysis. The outer edge of each region of Rosenthal’s canal was traced
using MetaMorph Offline™ software and the two – dimensional area was
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calculated by the software. The two – dimensional somatic area of SGCs with
clearly defined nuclei was assessed in the same way, and the number of these
SGCs per Rosenthal’s canal region was counted. Adobe Photoshop™ software
was used to adjust contrast levels in all images.
Data analysis
Log transformations on all psychophysical and electrophysiological data
points were completed to normalize psychophysical and electrophysiological
thresholds. For individual animal data, there were no differences seen in either
change over time (slope) or range (maximum–minimum values) in
psychophysical and electrophysiological thresholds. Therefore, all data points
throughout the 80 days test period were averaged to determine a threshold value
for each animal for each electrode configuration (six values for each animal)
(Figs. 2.3 and 2.5). Each of the electrode configurations tested represents an
independent variable, and Student’s t – test was used to determine differences
between experimental and control groups for each configuration.
The data for one configuration (A–B) was separated by date post –
implantation, and a two – way repeated measures ANOVA test was performed
on both psychophysical and EABR data (Figs. 2.4 and 2.6). Student’s multiple
comparison post – hoc tests determined specific differences between groups and
over time. EABRs were collected every two weeks and an average threshold and
standard deviation were determined for each of these dates for control and
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treated groups. Psychophysical detection thresholds were collected on a daily
basis, but not every configuration was run each day. In order to compare to
electrophysiological data, psychophysical threshold levels for each animal within
a two – week timeframe (i.e. data collected between 7 and 21 days post –
implantation) were averaged, and these values were used to determine a
psychophysical detection threshold average and standard deviation. To
determine differences in morphology, SGC density and cross – sectional somatic
area were compared between groups. The data from the three slides of each
individual were averaged to determine a mean cross – sectional somatic area for
each turn of the cochlea (lower basal, upper basal, middle, and apical) (Table
2.1). Density was calculated for each animal by dividing the average number of
SGCs within each region of Rosenthal’s canal by the average cross – sectional
area of that region. To eliminate the possibility of individual animal differences in
the area of Rosenthal’s canal, we compared the areas of this region for each turn
of the cochlea (Table 1). One – way ANOVAs and Student’s t – tests were used
to evaluate differences between the Ad.BDNF, Ad.Empty, and non – deafened
groups for each turn of the cochlea. Our non – deafened control group was
composed of the right, non – deafened, non – implanted, and non – inoculated
cochleae of both Ad.BDNF and Ad.Empty inoculated groups. Linear regressions
were used to determine correlations between psychophysical detection
thresholds and SGC density as well as between EABR detection thresholds and
SGC density. All analyses were completed using SigmaStat™ (Jandel Scientific).
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Ad.BDNF activity in vivo
In a separate experiment, six guinea pigs were inoculated with Ad.BDNF
(same concentration as above) in the left cochlea through the round window,
using the same surgical procedure as detailed above. One or two weeks post –
inoculation (n = 3 for each time point), animals were sacrificed, decapitated, and
both left and right temporal bones were removed. The basal turn of the cochleae
from each ear was carefully thinned using fine tipped forceps until a hole was
made in the basal turn outer wall. A micro – capillary tube was gently inserted
into this hole, and 1–2 !L of cochlear fluids were extracted from each cochlea.
Samples were diluted 100 fold using the sample diluent from a ChemiKine™
BDNF, Sandwich ELISA Kit (Millipore). This kit was used to determine BDNF
concentration in the cochlear fluids. The non – inoculated right ears of both
groups (n = 6) were used as controls. A one – way ANOVA was performed to
determine differences between the one week inoculated ears, the two week
inoculated ears, and the right, non – inoculated control ears.
Animal care
This study was performed in accordance with National Institutes of Health
Guidelines (Guide for the Care and Use of Laboratory Animals, 1996). The
University Committee on the Use and Care of Animals at the University of
Michigan approved the experimental protocols. Veterinary care and animal
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husbandry were provided by the Unit for Laboratory Animal Medicine, in facilities
certified by the Association for Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC, Int.).
2.3. Results
BDNF levels in vivo
The BDNF – ELISA revealed average concentration of BDNF in the right,
non – inoculated cochleae of 0.78 ng/ml (± 0.86) (Fig. 2.2). The concentration of
BDNF in the cochlear fluids one week following Ad.BDNF inoculation was 0.60 ±
0.66 ng/ml, similar to the non – inoculated ears. There was a marked increase in
BDNF concentration in the cochlear fluids tested two weeks post – inoculation,
3.7 ± 2.95 ng/ml. A one – way ANOVA revealed a statistically significant
difference between groups (p = 0.05), and a post – hoc multiple pairwise
comparison revealed that the two week group was significantly different from the
control group (p < 0.05).
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Fig. 2.2: BDNF concentration within cochlear fluids.
At two weeks post – inoculation, the concentration of BDNF within the cochlea
was significantly higher than the concentration of BDNF after one week, and
significantly higher than the right, non – inoculated ear.
One – way ANOVA, p < 0.05.
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Psychophysical detection thresholds
The Ad.BDNF treated group showed significantly lower psychophysical
detection thresholds than the Ad.Empty group in the apical bipolar configuration
(labeled A–B) (Student’s t – test, p = 0.03). Mean thresholds for the Ad.BDNF
group were also lower for the apical tripolar configuration (A–B–C), but this was
not significant (p = 0.06). For the monopolar configuration at the apical end of the
implant as well as all configurations at the basal end of the implant, thresholds for
the two groups were similar and not significantly different. Fig. 2.3 shows both
individual psychophysical detection thresholds, averaged over the entire testing
period (closed symbols), as well as group averages ± one standard error of the
mean (SEM) (open symbols with bars) for each electrode configuration tested.
The labels are arranged left to right along the x – axis from the apical end of the
implant for tripolar, bipolar, and monopolar configurations to the basal end of the
implant for tripolar, bipolar, and monopolar configurations.
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Fig. 2.3: Psychophysical detection thresholds averaged over time.
Each column represents a different electrode configuration. Closed symbols
represent averages over time of individual animal data points for each
configuration. Open symbols represent the group average (n = 4) and error bars
are ± standard error of the mean (SEM). Circles represent animals that received
Ad.BDNF inoculation and triangles indicate animals that received Ad.Empty
inoculation. Differences between groups were assessed via Student’s t – test; (*)
indicates p " 0.05. P – values for each configuration are as follows:
A–B–C: p = 0.06; A–B: p = 0.03; B–G: p = 0.61; C–D–E: p = 0.56; D–E: p = 0.38;
D–G: p = 0.68.
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Psychophysical threshold changes over time
The psychophysical detection threshold values did not significantly change
over time for either of the Ad.BDNF and Ad.Empty groups, but there was a
difference between group thresholds that was present throughout the
experiment. Fig. 2.4 shows psychophysical detection threshold averages for
each two week period of the experiment, using the A–B configuration data. A two
– way repeated measure ANOVA did not reveal a significant interaction between
group and time (p = 0.76) or a difference in time (p = 0.63), but did reveal a
difference between groups (p = 0.02). This suggests that the lower thresholds
seen in the A–B configuration for the Ad.BDNF group in Fig. 2.3, which were
thresholds averaged over the entire experiment time, were lower throughout the
length of the experiment and not dependent on time post – implantation.
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Fig. 2.4: Psychophysical detection thresholds over time, A–B configuration.
Each data point represents the average of psychophysical detection thresholds
collected in the preceding two week period for the four animals in each
experimental group. Most animals did not have valid thresholds in the first week
following implantation; data analyses therefore began with the third week
averages. Circles indicate Ad.BDNF treated animal averages and triangles
indicate Ad.Empty treated animal averages at each time point. Error bars indicate
± one standard deviation. A two – way repeated measures ANOVA revealed an
effect of group (p = 0.02) but not a significant effect of time (p = 0.63) or
interaction between time and group (p = 0.76). Post – hoc multiple pairwise
comparisons gave the following p – values: 3 weeks = 0.21; 5 weeks = 0.07; 7
weeks = 0.09; 9 weeks = 0.06; 11 weeks = 0.06.
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EABR thresholds
In both of the bipolar configurations (A–B and D–E), the Ad.BDNF group
had significantly lower electrophysiological thresholds than the Ad.Empty group
(Student’s t – test p = 0.002 for A–B and p = 0.03 for D–E). The difference
between groups was not significant in either of the monopolar configurations (p =
0.08 for B–G and p = 0.16 for D–G). Fig. 2.5 shows both individual EABR
thresholds, averaged over the testing period (closed symbols), and group
averages ± one SEM (open symbols) for each electrode configuration tested.
Labels on the x – axis in Fig. 2.5 are arranged left to right from the apical end of
the implant for bipolar and monopolar configurations to the basal end of the
implant for bipolar and monopolar configurations.
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Fig. 2.5: EABR thresholds averaged over time.
Symbols and statistical tests as in Fig. 2.3. P – values for each configuration:
A–B: p = 0.002; B–G: p = 0.08; D–E: p = 0.03; D–G: p = 0.16.
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EABR changes over time
The differences in EABR detection thresholds between treated and control
groups as a function of time were slightly different from those seen in
psychophysical detection thresholds. Fig. 2.6 shows the EABR detection
thresholds at each test date for the A–B configuration. A two – way repeated
measures ANOVA revealed a statistically significant interaction between group
and time (p = 0.01). Although the detection thresholds for both the Ad.BDNF and
Ad.Empty group were initially similar, there was a decrease in EABR thresholds
for the Ad.BDNF group as well as an increase in EABR thresholds for the
Ad.Empty group over time. For weeks 3 through 11 post – implantation, the
Ad.BDNF treated animals had significantly lower thresholds than the Ad.Empty
control group (p < 0.05).
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Fig. 2.6: EABR detection thresholds over time, A–B configuration.
Each data point represents a group average of thresholds obtained at each time
point indicated. Symbols as in Fig. 2.4. A two – way repeated measures ANOVA
revealed a significant interaction between group and time (p = 0.01), and (*)
indicates a significant difference between groups was found at that time point.
Post – hoc multiple pairwise comparisons gave the following p – values:
1 week = 0.47; 3 weeks = 0.03; 5 weeks = 0.02; 7 weeks = 0.03; 9 weeks = 0.03;
11 weeks = 0.04.
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Morphological changes
Upon dissection, each cochlea was visually inspected for markers of
trauma or infection, including broken bone, bony growth, opaque cochlear fluids,
and/or fluid in the middle ear space. There were no observed signs of a major
infection in any of the animals used in the study. In all animals included in this
study there was a loss of the organ of Corti structure following neomycin infusion
(Fig. 2.7). Image 2.7A shows the organ of Corti of an Ad.BDNF treated animal,
2.7B shows the organ of Corti of an Ad.Empty treated animal, and 2.7C shows
the organ of Corti of a right, non – deafened cochlea. These images are
representative of the basal, middle, and apical turns of all groups. A flat epithelial
layer with no hair cells or differentiated supporting cells, typical of ototoxic
deafening, was observed in all animals in the Ad.BDNF and Ad.Empty groups.
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Fig. 2.7: Light microscopy images of the organ of Corti structure
The basal turn organ of Corti is shown. (A) represents the Ad.BDNF group, (B)
represents the Ad.Empty group, and (C) represents the non – deafened, non –
inoculated control group. There are no hair cells or supporting cells visible in (A)
or (B), while inner hair cells (white arrow) and outer hair cells (black arrows) are
observed in non – deafened ears (C). Scale bar = 50 !m.
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SGC data were divided into lower basal, upper basal, middle, and apical
turns of the cochlea for analysis. There was a higher density of surviving neurons
in Ad.BDNF treated cochleae than in the Ad.Empty treated cochleae in the upper
basal turn region, but there was not a significant difference between these
groups in the lower basal, middle, or apical turns (Figs. 2.8 and 2.9). There are
two animals in the Ad.Empty group whose data for the lower basal turn are near
the level of that seen in the Ad.BDNF group. Because these animals received no
growth factor treatment, the level of SGC survival in this region of the cochlea,
which is physically closest to the implant, may reflect the influence of electrical
stimulation alone on SGC survival. Although it may appear that there are outliers
in the Ad.BDNF group (animals with high density values), the animal with the
highest SGC number is not the same in all cochlear regions.
The density for both Ad.BDNF and Ad.Empty groups was significantly
lower than the density for the non – deafened control group in all turns of the
cochlea (one – way ANOVA p < 0.01 for all cochlear turns); therefore, Fig. 2.9
shows data from only Ad.BDNF and Ad.Empty groups. There were no
differences seen between the non – deafened control group, the Ad.BDNF group,
and the Ad.Empty group in either cross – sectional SGC somatic area or cross –
sectional area of Rosenthal’s canal (Table 1). These data suggest that the
differences in SGC density between the Ad.BDNF and Ad.Empty groups was due
to an increase in the number of SGCs in the Ad.BDNF group, and not due to a
difference in the relative sizes of SGCs and Rosenthal’s canal.
41
Fig. 2.8: Light microscopy images of the upper basal and middle turn of an
Ad.BDNF (A, C) and an Ad.Empty (B, D) inoculated animal.
The basal turn Rosenthal’s canal (A, B) showed a greater number of surviving
SGCs in the Ad.BDNF treated ear (A) than the Ad.Empty cochlea (B). The middle
turn Rosenthal’s canal (C, D) showed little difference between treatment groups
in the number of surviving SGCs. Scale bar = 50 !m.
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Fig. 2.9: SGC density per cochlear turn.
Symbols as in Fig. 2.3. (*) indicates p " 0.05, Student’s t – test p – values were:












Ad.BDNF Lower Base 302.0 +/ –  55.5 64671.2 +/– 4909.4
Ad.Empty Lower Base 248.4 +/ –  45.3 74156.5 +/– 26004.3
Non–deafened control Lower Base 216.3 +/ –  46.9 59350.6 +/– 16377.2
Ad.BDNF Upper Base 286.5 +/ –  91.1 51404.9 +/– 5776.9
Ad.Empty Upper Base 223.4 +/ –  12.2 58849.8 +/– 6383.7
Non–deafened control Upper Base 170.8 +/ –  19.7 44544.9 +/– 6962.1
Ad.BDNF Middle 289.1 +/ –  118.2 45012.7 +/– 4427.3
Ad.Empty Middle 215.3 +/ –  44.8 45785.0 +/– 3562.7
Non–deafened control Middle 178.7 +/ –  35.8 46140.5 +/– 7044.0
Ad.BDNF Apex 266.5 +/ –  137.2 49895.4 +/– 29493.1
Ad.Empty Apex 201.9 +/ –  36.2 52449.1 +/– 11231.7
Non–deafened control Apex 202.5 +/ –  41.7 87128.1 +/– 32769.5
Table 2.1: Two – dimensional ganglion cell and Rosenthal’s canal
characteristics.
Listed are the group averages +/ –  one standard deviation for the SGC cross
sectional somatic area and cross sectional area of Rosenthal’s canal. Data are
separated into a lower basal, upper basal, middle and apical turns of the cochlea.
A one – way ANOVA analysis of each turn of the cochlea revealed no statistically
significant differences between groups.
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Correlation of results
The density of surviving SGCs was compared to both psychophysical
detection thresholds and EABR thresholds. Thresholds for the A–B configuration
were compared to SGC density values for the upper basal turn of the cochlea.
This electrode configuration and region of the cochlea showed the greatest
difference between the Ad.BDNF and Ad.Empty groups. We expected to see
lower thresholds for those cochleae that showed a higher density of surviving
neurons if the survival status of the auditory nerve directly affected cochlear
implant performance. Fig. 2.10 shows the psychophysical – SGC comparison
(2.10A) and the EABR – SGC comparison (2.10B). Regression analysis found a
significant relationship between the density of surviving SGCs and EABR
thresholds (F = 15.64, df = 1, 6, p = 0.008) and a non – significant relationship
between surviving SGCs and psychophysical detection thresholds (F = 0.25, df =
1, 6, p = 0.64). The relationship between EABR thresholds and the density of
SGCs was also highly correlated (r2 = 0.72). The slope of this linear regression
was negative ( – 2.97), indicating lower thresholds with increasing SGC number.
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Fig. 2.10: Relationship between thresholds and number of surviving SGCs
in (A) psychophysical testing and (B) electrophysiological testing.
Psychophysical detection thresholds and EABR thresholds from the A–B
configuration and SGC density values from the upper basal turn are compared.
Individual animal data points are plotted; circles represent animals that received
Ad.BDNF inoculation and triangles indicate animals that received Ad.Empty
inoculation. Lines represent linear regressions through all data points
(r2 = 0.04 in A and r2 = 0.72 in B).
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2.4. Discussion
In this study, a single inoculation of Ad.BDNF in combination with non –
continuous electrical stimulation promoted SGC survival 84 days post –
deafening and lowered psychophysical and electrophysiological thresholds for
cochlear implant stimulation for specific electrode configurations and locations.
Previous work on the effects of growth factors and electrical stimulation in the
cochlea have shown similar results with EABR and SGC measurements, but this
study was, to our knowledge, the first to address the effects of these post –
deafening treatments on psychophysical detection thresholds. This functional
measurement may be more clinically relevant and reflective of an animal’s ability
to hear with a cochlear implant than the electrophysiological assessment typically
collected from animal models of cochlear implant function. We have also shown
that Ad.BDNF inoculation into the cochlear fluids via the round window leads to
an increase in BDNF production within two weeks post – inoculation, providing a
link between the introduction of the adenovirus into the cochlea and our observed
morphological, physiological, and behavioral changes.
Long – term effects of adenoviral treatment and electrical stimulation
The current study assessed the morphological status of the auditory nerve
almost 12 weeks post – inoculation of Ad.BDNF, a relatively long time for
experiments on neurotrophic factors and auditory nerve survival. Previous in vivo
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work addressing the trophic effects of BDNF on the damaged auditory nerve
have examined SGC status at 2 weeks (Miller et al., 1997), 4 weeks (Shinohara
et al., 2002; Shepherd et al., 2005), and 8 weeks (Staecker et al., 1996) following
treatment initiation. Importantly, all of these studies used osmotic pumps to
supply a constant source of exogenous growth factors to the cochlea throughout
the testing period. The current study used one inoculation of Ad.BDNF and non –
continuous electrical stimulation and showed a high level of surviving SGCs in
the basal turn of the cochlea after 12 weeks. Although it appears that there was
an effect of Ad.BDNF treatment and electrical stimulation in both the lower and
upper basal regions, the difference between treatment groups was not significant
in the lower basal turn. This is the region of the cochlea where the implant was
located, and the similarities between groups in this region may reflect the
influence of direct electrical stimulation. Similar levels of electrical stimulation
have been shown to improve SGC survival, particularly in the vicinity of the
implant (Hartshorn et al., 1991). The greatest effect of our post – deafening
treatment was seen in the upper basal turn, and this may reflect either the spread
of the adenoviral transfection or the region of the cochlea in which BDNF has its
greatest influence.
In addition to long – term morphological effects, our treatment of a single
inoculation of Ad.BDNF in combination with electrical stimulation also had long –
term functional effects. Electrophysiological threshold levels assessed at regular
time intervals within the entire experiment showed an effect of time in the A–B
configuration. The thresholds for the Ad.Empty group worsened (increased) over
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time, whereas the thresholds for the Ad.BDNF group improved (decreased) over
this same period. Presumably, the auditory nerve was progressively
degenerating in the Ad.Empty group over this time period (Leake and Hradek,
1988), and this is what led to increased EABR thresholds. The decrease in EABR
thresholds for the Ad.BDNF group indicates that the Ad.BDNF inoculation in
combination with the electrical stimulation from the cochlear implant was
maintaining auditory nerve density and function by preventing post – deafening
degeneration and/or promoting neural regrowth, either of which would have a
positive effect on cochlear implant function.
Psychophysical and electrophysiological thresholds
Our data show an effect of adenoviral – mediated up – regulation of BDNF
and electrical stimulation on two measures of the cochlear implant function,
psychophysical detection thresholds and EABR thresholds. However, the results
for these two measures are not identical. The greatest effect on psychophysical
detection of cochlear implant stimulation was seen at the apical end of the
implant. Electrode configuration A–B was the only tested configuration where the
introduction of Ad.BDNF  led to a statistically significant improvement in
psychophysical thresholds. This configuration used the two most apical
electrodes on the implant as stimulating and return channels. The implant
insertion method used in this study (through a cochleostomy) typically places the
electrodes at the apical end of the implant close to the modiolus, as this end of
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the implant fills the scala tympani. Depending on the individual implantation, the
basal end of the implant could either hug the modiolus or arc outward. The
location of the electrodes at the basal end of the implant therefore probably
varied across animals between close to modiolus and close to the outer scala
tympani wall. This means that the A and B electrodes were more likely than other
electrodes to be physically closest to Rosenthal’s canal and surviving SGCs, and
would probably stimulate a more restricted portion of the nerve. The apical
tripolar configuration, labeled A–B–C, also used the most apical electrodes in the
implant, and the data for this configuration showed a similar trend to that seen in
the A–B configuration, where psychophysical detection thresholds were lower in
the Ad.BDNF treated group than in the Ad.Empty group. However, the monopolar
configuration at the apical end of the implant (B–G) did not show a difference
between groups. Because of the distance between stimulating and return
electrodes, bipolar and tripolar configurations typically stimulate a more discrete
group of neurons than monopolar configurations. These data suggest that for
psychophysical detection thresholds with cochlear implant stimulation, focused
electrical stimulation nearest to the auditory nerve is most likely to show
differences in SGC survival.
Electrode configuration, but not necessarily the distance between the
implant and the nerve, played a role in determining effects of our post –
deafening treatments on EABR thresholds. In our EABR data, the greatest
difference between the Ad.BDNF and Ad.Empty groups was seen in the A–B and
D–E configurations. These were bipolar configurations that used electrodes at
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both the apical (A–B) and basal (D–E) end of the implant. We did not see an
effect of treatment on either monopolar configuration tested. These data suggest
that for electrophysiological thresholds with cochlear implant stimulation, a
smaller spread of excitation is most likely to show differences in SGC survival,
even if the source of that excitation is farther from the nerve itself, as in the basal
end of the implant bipolar configuration (D–E). Both of the functional measures
used in this study suggest that focal stimulation of the surviving auditory nerve
may best reveal an effect of growth factor and electrical stimulation treatment.
Both psychophysical and electrophysiological thresholds are important
functional indicators of the effect of neurotrophic treatments on auditory nerve
survival. The EABR is a gross field potential measurement, and requires the
synchronized activation of a large number of neurons. Psychophysical responses
may or may not require a similar degree of synchronicity as in the EABR. Our
EABR thresholds correlated better with the density of surviving SGCs than did
the psychophysical detection thresholds. By requiring a high level of synchrony
between neurons in order to obtain a response, EABR thresholds may be a
better indicator of the pathological disruptions in the timing of the surviving nerve
activation. However, this coarse metric of auditory nerve status may not be
completely indicative of an animal’s ability to perceive and process sound from
the cochlear implant.
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Ad.BDNF transgene expression and electrical stimulation
The levels of electrical stimulation provided to the cochlea to obtain the
data for our functional measures are similar to levels that have previously been
shown to improve SGC survival (Hartshorn et al., 1991; Mitchell et al., 1997).
This stimulation may have helped maintain auditory nerve survival throughout our
experiment, as viral constructs are effective in the cochlea for a few weeks at
most (Raphael et al., 1996; Weiss et al., 1997). Using the same vector as in this
study, Di Polo et al. (1998) saw a peak of Ad.BDNF expression at 7 days after
inoculation into the retina and no expression beyond 14 days post – inoculation.
As our study continued until almost 12 weeks, it is unlikely that transfected cells
were still secreting BDNF at the end of the experiment. Rather, BDNF levels
were probably high in the first few weeks after viral vector inoculation, as
indicated by our ELISA data, and returned to baseline levels later. At that point,
electrical stimulation may have contributed to the survival and functionality of the
neurons. Our results are consistent with the idea that continued electrical
stimulation could provide significant protective effects once growth factor
secretion or application is diminished (Shepherd et al., 2008).
Substantial immune response is not typically seen in the cochleae of
guinea pigs after one inoculation of adenovirus vectors, especially when the
animals are specific – pathogen – free and have not experienced an adenovirus
infection prior to the experiment (Raphael et al., 1996; Ishimoto et al., 2002). The
empty vector control used here was an advanced generation vector and less
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likely to cause an immune reaction than the first generation vector Ad.BDNF,
although we did not see any major indications of an immune response in either
the Ad.BDNF or the Ad.Empty groups. Still, a mild and not easily detectable
response to the virus may occur, which we expect is more likely with first
generation vectors than with later generation vectors. Our outcome may
therefore be an under – estimate of the protective ability of BDNF, because the
adenovirus itself may have elicited some negative side effect. Indeed, the
variations in the construction of viral vectors can make comparison of viral vector
efficacy somewhat difficult. However, it is clear that gene therapy such as that
used in this study can be effective in treating inner ear damage and in influencing
auditory nerve function.
There is an ongoing discussion regarding the cochlear gradients of BDNF
and NT – 3 and their respective high – affinity receptors in the adult cochlea. The
developmental patterns of BDNF and NT – 3 expression are well established
(Fritzsch et al., 1999; Farinas et al., 2001). However, there is some evidence that
pattern of expression changes location over time (Adamson et al., 2002;
Schimmang et al., 2003). It may be possible that the increased SGC survival we
have seen exclusively in the basal turn is related to the choice of neurotrophic
factor in our viral construct. The use of Ad.NT – 3 or a combination of Ad.BDNF
and Ad.NT – 3 may provide more survival in the middle and apical turns if there
is a greater effect of NT – 3 than BDNF in these regions of the adult cochlea.
Concentration gradients related to preferential transgene expression in the basal
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cochlea may have also contributed to the difference seen here between effects in
basal and more apical regions of the cochlea.
We found that the introduction of Ad.BDNF in conjunction with the
electrical stimulation required for psychophysical and EABR testing led to
decreased psychophysical and EABR thresholds as well as increased SGC
survival in deafened guinea pigs. The current results add to previous research
supporting the use of neurotrophins in combination with cochlear implants to aid
in rehabilitation for severe sensorineural hearing loss. We also extend the clinical
relevance of this approach by including multiple functional assessments and by
using relatively long – term treatments in the deafened cochlea. We found a
demonstrable behavioral effect of adenoviral – mediated changes in BDNF gene
expression and electrical stimulation of the deafened cochlea over a period of 80
days. In addition, the results from this study highlight the need for several
measurements of auditory nerve function, as EABR and psychophysical
thresholds showed different patterns following treatment. Attention should be
paid to both electrode configuration and the location of the electrode with respect




Visualization of spiral ganglion neurites within the scala tympani with a
cochlear implant in situ
3.1. Introduction
In mammals, cochlear hair cell loss is a permanent and irreversible event,
which often initiates auditory nerve deterioration. This nerve degeneration begins
at the level of the afferent and efferent processes that innervate the hair cells,
and may continue with the primary ganglion cell bodies (Spoendlin, 1975). In
such cases of severe hearing loss, cochlear implants (CIs) offer an effective
treatment option. CIs function by electrically stimulating the remaining auditory
nerve and bypassing the function of lost hair cells. The status of the nerve, and
its ability to receive and process electrical signals, is therefore a critical factor in
the success of cochlear implantation. While mammalian hair cells cannot
currently be regenerated to a functional level, there is well – established
evidence that the introduction of growth factors can promote auditory nerve
ganglion cell survival following hair cell loss (Marzella and Clark, 1999; Roehm
and Hansen, 2005). In addition, it has been shown that an increase in ganglion
cell survival is
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correlated with improved electrophysiological thresholds to CI stimulation
(Yamagata et al., 2004; Shepherd et al., 2005).
Once distal processes are regressed, the primary auditory neurons remain
relatively far from the CI stimulation source. It may be beneficial for CI users if
the peripheral processes of the auditory nerve could be preserved or directed to
regrow towards and make contact with a CI. Decreasing the distance between
the auditory nerve and the CI has been shown to lower thresholds and decrease
the spatial spread of excitation in human CI patients (Cohen et al., 2005), animal
subjects (Shepherd et al., 1993), and model systems (Briaire and Frijns, 2006).
By stimulating nerve fibers instead of the more distant cell bodies, a lower level
of current may be required to elicit a neural response, which may increase the
battery life of the implant and reduce cellular damage. Battery power is a limiting
factor in the parameters of electrical stimulation available from a CI; increasing
the battery life could allow for more complex stimulation strategies. In addition,
there is the potential for increased specificity of electrical stimulation and reduced
channel interaction when neural impulses are initiated at nerve fibers instead of
the cell body. Any of these improvements in electrical signal processing could
improve the hearing experience for CI recipients.
Spontaneous regeneration of auditory nerve peripheral processes has
been reported in mammals following both acoustic trauma (Bohne and Harding,
1992; Lawner et al., 1997) and aminoglycoside ototoxic deafening (Webster and
Webster, 1982). Growth factor – induced regeneration of nerve fibers has also
been seen both in vivo and in vitro (Malgrange et al., 1996; Staecker et al., 1996;
56
Cho et al., 1998; Wise et al., 2005; Glueckert et al., 2008). In vivo studies have
shown fiber growth both within the habenula perforata, where processes are
normally located (Wise et al., 2005; Glueckert et al., 2008), as well as within the
scala tympani (ST), the fluid – filled space within the cochlea where CIs are
placed (Leake and Hradek, 1988; Staecker et al., 1996). While several lines of
research are aimed at promoting peripheral processes regrowth into the ST to
contact a CI, current histological assays are not well suited to visualizing the
results. If future work on auditory nerve regeneration proceeds to the level of
directing growth to make contact with a CI, it will become necessary to visualize
the implant and the regenerated fibers simultaneously while minimizing the
perturbation of the regrown nerve fibers.
Typical cochlear preparations involve decalcification, embedding, and
sectioning to produce mid – modiolar images of the interior of the cochlea. These
mid – modiolar sections do not allow visualization of both the implant and the
scala tympani because highly specialized sectioning tools are required to cut
through the metal wire used in the construction of CIs, and the implant must
therefore be removed prior to analysis. Surface preparations of various cochlear
structures are also commonly used, but this technique typically exposes only one
surface. Any microscopic analysis would require plating and coverslipping the
specimen, eliminating the ability to examine the space within the ST. Inverted
confocal microscopes are also unsuitable because the magnification levels are
typically too high for proper visualization of the entire implant and its spatial
relationship with the cochlea. We have therefore developed a technique that
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utilizes a stereoscope to view the intact cochlear and preserves the placement of
the CI, yet allows visualization of fluorescently – labeled neuronal fibers and
preserves the spatial relationship between the two. The method detailed in this
paper includes both a specialized cochlear dissection and the subsequent tissue
processing. This method represents a novel visualization technique that provides
a means for characterizing the presence and location of nerve fibers within the
scala tympani with respect to a CI in a way that preserves the fidelity of the in
vivo relationship.
3.2. Methods and materials
Subjects
Eleven male, pigmented guinea pigs (Elm Hill, Chelmsford, MA) were
used in this study. Guinea pigs have cochleae that are mature at birth, similar to
humans, which makes them a better animal model for cochlear implant research
than other rodents. Animal weights ranged from 400 – 600 g at the time of
implantation. Following systemic deafening, animals were implanted with two –
electrode CIs through a cochleostomy near the round window. Animals retained
their implants for four weeks, after which they were sacrificed for temporal bone
removal and cochlear dissections. This study was performed in accordance with
National Institutes of Health Guidelines (Guide for the Care and Use of
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Laboratory Animals, 1996). The University Committee on the Use and Care of
Animals at the University of Michigan approved the experimental protocols. The
Unit for Laboratory Animal Medicine at the University of Michigan provided
veterinary care and animal husbandry, in facilities certified by the Association for
Assessment and Accreditation of Laboratory Animal Care, International
(AAALAC, Intl).
Deafening procedure
Animals were systemically deafened using a combination of kanamycin
(400 mg/kg, SQ) and ethacrynic acid (40 mg/kg, IV, two hours following
kanamycin). This procedure is a standard means of mimicking human hearing
loss, and effectively eliminates cochlear hair cells bilaterally (West et al., 1973;
Xu et al., 1993). Hearing loss was confirmed with auditory brainstem responses
(ABRs). ABRs were measured prior to deafening and four weeks post –
deafening and hearing loss was defined as a shift of 40 dB SPL between the two
measurements. Hair cell loss was confirmed with post – mortem histological
analysis. Animals were deafened prior to implantation to initiate a regression of
peripheral processes and increase the likelihood of fiber growth into the ST.
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Implant construction
Implants consisted of two stimulating electrodes and were constructed in –
house, as previously described (Miller et al., 1995). Briefly, a wire electrode was
wrapped in a helix (300µm length and diameter) around an insulated wire leading
to ball electrode (450µm diameter). All wires were platinum/iridium (A & M
Systems, Sequim, WA). The lead wires from the electrodes were threaded
through a piece of silicone tubing 35 mm long and connected to a base pedestal.
The implant was inserted approximately 2 mm into the ST (Fig. 3.1 and Fig. 4.1).
Implantation
All animals were unilaterally implanted in the left ear. For general
anesthesia, animals were given a mix of ketamine (40 mg/kg) and xylazine (10
mg/kg) (IM). Animals were also given atropine (0.05 mg/kg, SQ) to aid in
respiration, and kept warm using a heating blanket. Lidocaine was used as a
local anesthetic, and an incision was made in an arc caudal to the pinna of the
ear to be implanted. The underlying muscle and tissue were pushed back to
reveal the bulla and a small hole was made in the bulla with the tip of a scalpel
blade, exposing the middle ear space, the basal turn of the cochlea, and the
round window. A bone drill and a 0.7 mm diamond burr was used to make a
cochleostomy in the wall of the ST apical to the round window, and the two –
electrode CI was placed into the ST. Implants were inserted approximately one –
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third to one – half of the way into the basal turn of the cochlea. A secondary hole
was made in the bulla, and a silk suture was threaded through the two bulla
holes and used to tie the implant to the temporal bone and prohibit movement of
the implant within the cochlea. Carboxylate cement covered both holes in the
bulla and secured the position of the implant. The silicone tubing containing the
lead wires of the implant was tunneled under the skin from the incision behind
the ear to the midline of the skull where the implant base pedestal was secured
to the skull of the animal using screws and dental acrylic. The skin incision was
sutured in two layers and the animal was given warm subcutaneous saline and
yohimbe (1 mg/kg) to reverse the effects of xylazine and aid in recovery.
Sacrifice and initial dissection
Four weeks post – implantation, animals were given an overdose of
anesthesia (as above) and decapitated. Excess tissue and muscle from the neck
and head was carefully removed until the silicone tubing of the implant leading
into the left temporal bone was visible. The implant was cut with scissors outside
the temporal bone and the remainder of the connective tissue and muscle
attached to the temporal bone was removed so that the entire left (implanted)
temporal bone could be dissected out. The right temporal bone was also
removed. Each temporal bone was immediately submerged in 4 %
paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH = 7.3). While in
4 % PFA, the temporal bone was carefully trimmed to reveal the cochlea. The
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region of the temporal bone that contained the carboxylate cement and silk
suture, which held the implant in place, was left undisturbed. A small portion of
the bone covering the apex of the cochlea was removed and one to two mL of
PFA were locally perfused into the fluid spaces of the cochlea via this apical hole.
The entire temporal bone, with the implant held in place by the suture tie in the
bulla, was left in 4 % PFA for 24 hours to allow thorough fixation.
Basal cochlear bone removal
Following fixation, temporal bones were rinsed in PBS and placed in a 35
mm Petri dish in PBS. The temporal bone was trimmed such that the cochlea
and the portion of the temporal bone that held the implant in place remained
intact and the implant was immobile. The bone where the basal turn of the
cochlea meets the temporal bone wall (black arrow, Fig. 3.1) was carefully
thinned using a bone drill and a 3.0 mm carbide cutting burr (Osteon™). Once
the bone was thin and translucent, a 1.0 mm diamond burr (Osteon™) was used
to carefully create a cochleostomy in the basal cochlear wall, apical to the
original implant cochleostomy. This hole was carefully expanded (dashed line,
Fig. 3.1), using either the 1.0 mm diamond burr or fine – tipped forceps, to
approximately 3 mm long, until the entire CI within the ST could be visualized.
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Fig. 3.1: Basal cochlear dissection with implant in place.
The left cochlea of a guinea pig is shown with the in – house constructed
cochlear implant within the scala tympani four weeks post – implantation. The
basal cochlear bone around the implant was carefully removed to reveal the
location of the implant within the scala tympani without disturbing the implant or
tissue within the cochlea. The dashed line indicates the perimeter of the area of
bone removal. The black arrow shows the dissection starting point, where the
temporal bone meets the cochlea and the bone is very thick relative to the rest of
the cochlear bone. The white arrow indicates the original cochleostomy where
the implant was inserted into the cochlea. Labels: b = ball electrode, h = helix
electrode, ST = scala tympani, SV = scala vestibuli. Scale bar = 500µm.
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Immunohistochemistry and fluorescent stereoscopy
Following removal of the basal turn outer wall, the entire temporal bone
specimen was rinsed by submerging it twice in PBS for 5 minutes each.
Specimens were permeabilized in 0.3 % Triton X – 100 (Sigma) for 10 minutes
and rinsed with PBS for 5 minutes. Specimens were then exposed to a mouse
monoclonal anti – neurofilament antibody (160kD, Millipore) diluted 1:100 in PBS
/ 0.1 % bovine serum albumin (BSA, Sigma) / 1 % goat serum, for one hour at
room temperature. The 160kD neurofilament subunit was chosen for this study
because it labels both type I and type II ganglion cells and their processes and
labeling is not dependent on phosphorylation (Berglund and Ryugo, 1991). For
this primary antibody step, which would have required a large amount of antibody
to fully submerge the entire temporal bone, specimens were placed cochlear side
down in a glass vial and enough solution was added to fully cover the cochlea
but not all of the temporal bone (approximately 1 mL). During the soaking time,
several local perfusions of the primary antibody solution were rinsed directly into
the cochlea. Specimens were rinsed twice in PBS / 0.1 % BSA / 1 % goat serum,
for 5 minutes each, and then placed into a solution containing the secondary
antibody: goat anti – mouse FITC (Jackson), diluted 1:200 in PBS / 0.1 % BSA /
1 % goat serum. Specimens were left in the secondary antibody solution
overnight at 4°C. As with the primary antibody solution, temporal bones were not
completely submerged in the secondary antibody solution, but instead only the
cochlear portion was covered. Following the overnight incubation, the tissue was
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rinsed three times with PBS for 5 minutes each. Specimens were observed and
photographed under a Leica MXFL III stereo fluorescence microscope (Leica,
Eaton, PA) equipped with a 10x eyepiece, a 1.6x lens, and 0.8 – 10x focus knob.
This allowed for a magnification range of 12.8x – 160x. Adobe Photoshop™
software was used to adjust contrast levels in all images.
3.3. Results
Our neurofilament immunohistochemistry protocol was successful in
labeling the auditory nerve and the spiral ganglion neurites in the scala tympani
with a cochlear implant in situ. These processes could be visualized in the same
field of view as the implanted electrode with a low – magnification stereoscope,
following our cochlear dissection, which left the implant intact within the cochlea.
Immunohistochemistry of the central auditory nerve
The auditory nerve central processes in each temporal bone were
examined under fluorescent light to verify successful labeling of neurons with
neurofilament. Each temporal bone was turned cochlear side down (apex down)
to reveal the auditory nerve as it exited the temporal bone at the internal auditory
meatus. This was the region of the auditory pathway where the nerve would pass
from the internal auditory meatus to the cochlear nucleus in an intact system.
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However, because only the temporal bone itself was preserved for dissection and
immunohistochemistry, the auditory nerve was severed from the rest of the
auditory pathway and could be visualized. Images of the nerve were taken in
both bright light and fluorescent light, and Fig. 3.2 shows an example of
fluorescing auditory nerve fibers. This image contains two control specimens that
verify the specificity of our immunohistochemistry protocol. The specimen in Fig.
3.2A & B received the full immunohistochemical protocol, the specimen in Fig.
3.2C & D did not receive the primary antibody step of the protocol, and the
specimen in Fig. 3.2E & F did not receive any staining. There were no fluorescing
fibers seen in the auditory nerve of any specimen that did not receive the full
immunohistochemical protocol. The images under fluorescent light (right panel,
Fig. 3.2B, D, F) show the auto – fluorescence of the temporal bone. There was a
noticeable lack of illumination in the region where the auditory nerve was (black
dashed lines) without the full immunohistochemical protocol (Fig. 3.2D, F) but a
significant increase above background levels in the auditory nerve that received
the full protocol (Fig. 3.2B). Fluorescing central auditory nerve fibers were
verified in all specimens prior to further analyses.
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Fig. 3.2: Neurofilament staining of the central auditory nerve.
The auditory nerve as it exits the internal auditory meatus is shown under bright
light (left panel) and fluorescent light (right panel). Dashed lines indicate the
auditory nerve. Neurofilament – labeled fibers are visible within the auditory
nerve under fluorescent light at mid – level magnification (51.2x) only in tissue
samples that underwent the entire immunohistochemical protocol (A, B) and not
in samples that did not receive the primary antibody (C, D) or did not receive any
staining (E, F). Scale bar = 200!m
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Immunohistochemical visualization of neurofilament – labeled processes within
the scala tympani
Fig. 3.3 shows both bright light and fluorescent light images of the
exposed ST from one animal at two magnification levels. At lower magnification
levels (Fig. 3.3A & B), neurofilament – labeled processes are visible where the
central auditory nerve exits the temporal bone (black arrow), as well as within the
scala tympani (white arrow). As the magnification level was increased (Fig. 3.3C
& D), neurofilament – labeled processes could be seen more clearly (white
arrows). The scala tympani from three additional animals are shown in Fig. 3.4.
Fig. 3.4A and 3.4B demonstrate that it was possible to view single fibers and the
implant in the same view. At the highest level of magnification possible with the
Leica stereoscope, 160x, neurofilament – labeled fibers) are visible in the direct
vicinity of the implant (white arrows, Fig. 3.4B). Fig. 3.4C shows a normal non –
deafened, non – implanted cochlea following our immunohistochemical protocol,
where no neurofilament – labeled fibers were visible within the scala tympani.
Six out of the eleven implanted cochleae (55 %) that were examined
exhibited neurofilament – labeled processes within the scala tympani. Our
visualization technique allowed us to see neurofilament – labeled processes in
various locations throughout the basal turn of the cochlea, including near the
lateral cochlear wall (Fig. 3.4A), near the cochlear implant (Fig. 3.4B), near the
original cochleostomy, and near the basilar membrane. This diversity was
expected, as peripheral processes growth can be random and disorganized
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(Bohne and Harding, 1992; Staecker et al., 1996), and there is currently no
method to consistently attract nerve growth into the scala tympani. In addition,
some cochleae exhibited fibrotic tissue growth within the scala tympani, which is
common with long – term cochlear implantation (Ni et al., 1992; Shepherd et al.,
1994). This tissue growth did not label with the neurofilament antibody, indicating
that our labeling process was specific to neuronal processes only.
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Fig. 3.3: Neurofilament staining within the cochlea.
The interior of the cochlea and the cochlear implant (b = ball electrode) following
our dissection from the same specimen is shown at two magnification levels,
under bright light and fluorescent light. (A) and (B) are low magnification images
that show the entire cochlea, and the central auditory nerve exiting the temporal
bone shows neurofilament – positive fibers (black arrow). (A’) and (B’) are middle
magnification level images and neurofilament – labeled processes are visible
within the scala tympani under fluorescent light (white arrows).
Scale bar = 500µm.
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Fig. 3.4: Examples of neurofilament labeling within the cochlea.
Images from three different animals are shown. In (A), the ball electrode of the
cochlear implant (b) and neurofilament – positive processes (white arrow) can be
seen in the same view, although the implant was at a lower focal plane than the
processes. In (B), at the highest magnification level possible with the
stereoscope used here (160x), the implant electrode was clearly recognizable
and individual processes can be seen (white arrows). In (C), a normal, non –
deafened, non – implanted cochlea does not show any neurofilament – positive
fibers within the scala tympani, ST = scala tympani, SV = scala vestibuli. Scale
bar = 200µm in all images, dashed lines indicate the area where the lateral wall
of the cochlea was removed to view the implant.
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3.4. Discussion
In this study, we show that it was possible to visualize neuronal fibers at
stereoscopic levels in relation to a CI in situ. Our technique leaves the CI in place
within the cochlea, allows for very little movement of the implant during
processing, allows visualization of the space within the ST, and reduces damage
to cochlear tissue by performing minimal dissection. This represents a new
technique to aid experiments that need to characterize the physical relationship
between neurites and a CI in vivo.
The highest magnification level available with the stereoscope used in this
study was 160x, a relatively low level compared to other histological methods.
However, this level was sufficient to show individual nerve processes within the
scala tympani (Fig. 3.4B). Lower magnification levels also showed fibers in both
in the central auditory nerve (Fig. 3.2) and the scala tympani (Fig. 3.3). These
figures demonstrate that the method described here can simultaneously provide
images of the small nerve fibers and the larger implant, as well as the three –
dimensional space around them.
The method described here may be best employed in conjunction with
other cochlear histology methods. Due to the size of the implant, a stereoscope
is necessary to visualize the entire implant within the cochlea, but the coarse
nature of stereoscopic focus may make it difficult to determine the exact location
of fluorescently – labeled fibers within the ST. Finer resolution could be found
using mid – modiolar sectioning, whole mount preparations of the basal turn, or
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confocal microscopy, any of which could be implemented following the method
described in this paper. For example, a series of z – stacks using a confocal
microscope could provide images that are more accurate and include more detail
of the location of fluorescently – labeled fibers. However, the stereoscope must
first be used to determine the general location of fibers because the high
magnification of the confocal microscope does not permit visualization of the
entire implant and the fibers in the same view. The technique described in this
paper could therefore be an important preliminary histological step in auditory
nerve regeneration studies.
This technique should be used as qualitative assessment of neurites
within the cochlea and not a quantitative metric, for several reasons. First, the
focal adjustments on the stereoscope are not fine enough to ensure accurate
imaging of neurites. Second, there is limit to the time spent capturing images of
fluorescing fibers, and anti – fade medium cannot be applied to these specimens
because of air exposure. Individual variability in the strength of labeling is quite
possible with images taken without anti – fade medium due to the length of light
exposure prior to image capture. This can be seen in the difference in signal
strength between the central nerve fibers seen in Fig. 3.2 and the peripheral
fibers seen in Fig. 3.3. The images of the central nerve fibers were taken prior to
the images of the peripheral nerve fibers, to verify successful
immunohistochemical processing. The processes in the scala tympani images
therefore received longer light exposure and did not fluoresce as brightly as the
central nerve fibers. Finally, there is the possibility that fibers grew medial to the
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cochlear implant and were blocked from view by the implant. These neurites
could be seen in cross sections of the cochlea, and potentially counted in these
images, but these sections are taken after implant removal, which will most likely
disrupt or shear any fibers that have grown within the scala tympani. Any of these
complications would likely make any neurite count an underestimate.
While we focused on neurofilament labeling, this protocol could be easily
adapted for use with a host of neuronal and synaptic markers.  Neurofilament
labeling does not tell us whether the nerve growth seen within the scala tympani
was afferent or efferent, regenerated fibers, or whether the nerve is functional.
However, other markers, such as ChAT, synapsin, or GAP43, that could further
define the fiber growth. Additional immunohistochemistry could be performed
following this initial characterization, allowing gross visualization of nerve
processes while not precluding the use of sectioning if microanalysis is also
desired. Modifications to the immunohistochemical protocol, such as the choice
of blocking agent and antibody hosts, should be considered if further labeling
would occur.
The current paper does not attempt to regrow auditory nerve peripheral
processes, but rather develop a method for visualizing nerve fibers and their
spatial relationship to a cochlear implant. Animals were deafened prior to
implantation and tissue processing to disconnect peripheral processes from hair
cells and encourage growth into the scala tympani. Indeed, neurofilament –
labeled processes were only seen within the deafened cochleae, not within the
non – deafened cochleae (Fig. 3.4). Growth of these processes into the scala
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tympani following hair cell loss has been seen previously (Leake and Hradek,
1988; Staecker et al., 1996). The fibers seen in these previous studies and in the
images of this paper (Fig. 3.3 and Fig. 3.4) exhibited uncontrolled and indistinct
growth patterns. The technique detailed in this study could provide a valuable
tool for viewing nerve growth and help to refine future experiments directed at
controlling and promoting the regrowth of auditory nerve fibers. This method
provides an easily adaptable means to view fibers within the three – dimensional
space of the scala tympani in conjunction with a cochlear implant.
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Chapter 4
Cochlear implant hydrogel coating promotes auditory nerve fiber growth
within the scala tympani in direct vicinity of implant
4.1. Introduction
Cochlear hair cells are the sensory transducing cells of the auditory
system and innervate the primary cell bodies of the auditory nerve, spiral
ganglion cells (SGCs). Peripheral processes extend from the hair cells in the
basilar membrane through the habenula perforata, osseous spiral lamina, and
connect to SGCs. Hair cell loss is a common cause of hearing loss, is caused by
a number of environmental and genetic variables, and is irreversible in mammals.
Once hair cells are lost or no longer functional, the peripheral processes and
SGCs often degenerate as well (Spoendlin, 1975), due to the loss of both
electrical and chemical stimulation. While the regeneration of mammalian
cochlear hair cells is currently under investigation (Izumikawa et al., 2005), there
is presently no clinical approach to restore hearing through these cells. In cases
of severe to profound hearing loss, cochlear implants (CIs) offer a way to bypass
the function of hair cells and directly stimulate the auditory nerve. CIs have been
quite effective in providing hearing to patients for several decades, but users still
have difficulty processing complex sounds such as music.
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Compared to other implantable prostheses, the cochlear implant is located
relatively far from the stimulated tissue. The implant is placed into the scala
tympani, one of three fluid – filled space of the cochlea. Spiral ganglion cells are
located within the center of the cochlea and separated from the implant by bone,
tissue, and fluid. Thus, a large amount of current is needed to stimulate the
auditory nerve, which can lead to diffuse stimulation from each electrode,
overlapping current fields, and channel interaction. In addition, high current levels
consume more battery power. However, if the distance between the nerve and
the electrodes were reduced, more discreet stimulation and lower battery
consumption are possible, which could provide better processing of complex
sounds. Physiological studies of cochlear implant stimulation have shown that a
shorter distance between the ganglion cells and the implant can lower thresholds
to electrical stimulation (Shepherd et al., 1993; Cohen et al., 2005), and model
studies suggest that stimulating the nerve fibers instead of cell bodies can
improve the fidelity of the signal and lower thresholds (Stypulkowski and van den
Honert, 1984; Colombo and Parkins, 1987)
Spontaneous resprouting of the auditory nerve peripheral processes has
been seen in mammals following both acoustic trauma and aminoglycoside
induced hair cells loss (see Chapter 3). These regenerated fibers are quite
variable in quantity and location, but give evidence that there may be opportunity
for interventions to promote nerve fiber survival and growth in addition to
improving SGC survival. In animal models, the introduction of neurotrophic
factors, particularly neurotrophic factor 3 (NT – 3) and brain – derived
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neurotrophic factor (BDNF), when introduced following hair cell loss, can promote
somatic survival (Hartnick et al., 1996; Staecker et al., 1996; Gillespie et al.,
2003), and regrow peripheral processes (Malgrange et al., 1996; Wise et al.,
2005). While these studies show that it is possible to regrow the deafferented
auditory nerve, it has not yet been shown that this regrowth can be directed
toward a cochlear implant in vivo.
Attempts to direct growth of nerve processes to make contact with an
intracochlear implant are hindered by the location of the implant, within the scala
tympani in perilymphatic fluid, which does not provide a substrate for neurites to
grow on or give directional cues. We have therefore developed a cochlear
implant coating that was designed to provide both an extracellular matrix on
which neurites can attach and extend processes as well as a chemotropic target
to direct growth. This coating was composed of an alginate hydrogel that has
been modified to include the arginine – glycine – aspartate (RGD) motif (Rowley
et al., 1999) and was applied to the implant prior to implantation and encircles the
implant. This gel forms a lining between the implant and the cochlea, which
increases biocompatibility of the implant and aids neurite growth by creating a
scaffold within the scala tympani on which neurites can grow. In addition, the
composition of the hydrogel makes it an excellent vehicle for drug delivery, as the
gel can be hydrated in a solution containing a drug of interest, which was
absorbed into the gel and slowly released from the gel once the implant was
placed in the scala tympani. BDNF was the growth factor of choice in this study,
and we hypothesized that the slow release of BDNF from the coating would
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provide a chemoattractant source to direct auditory nerve process regrowth
toward the cochlear implant.
4.2. Methods and Materials
Implant Construction and Coating
Cochlear implants were made in – house as previously described
(Chapter 3) (Miller et al., 1995). Briefly, a platinum – iridium wire (A & M
Systems, Sequim, WA) was used to construct a ball electrode (450 µm
diameter), around which another wire was wrapped to create a helix shape (300
µm length and diameter). A piece of polyimide 2 mm long separated and
insulated the two wires (Fig 4.1). The lead wires from the two electrodes were
threaded through silicone tubing and connected to a pedestal that held the wires
in place. Liquid silastic was used to seal the junction between the ball electrode
and the polyimide and between the silicone tubing and the two lead wires.
Implants received either a hydrogel + BDNF coating, a hydrogel – only
coating, or no coating at all. Hydrogel coatings were applied by dipping the
implant into two solutions. The first solution was 1 % RDG – alginate in PBS. The
second solution was 2 % CaCl2 in PBS, which cross – linked the polysaccharide
chains of the alginate. Implants were dipped in this combination of solutions four
times, to build up a coating on the implant that was approximately 50 !m thick
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(Fig. 4.1). The gel was then dehydrated in open air and the implant was sterilized
for surgery using ethylene oxide.
Immediately prior to implantation, implants from the hydrogel + BDNF
group were placed in 10 !l of 400 ng/ml human recombinant BDNF (Millipore) for
45 minutes in a 1.5 mL microcentrifuge tube. This volume was sufficient to
completely cover the hydrogel – coated end of the implant. Implants were
dehydrated for 20 minutes prior to implantation to allow ease in insertion and to
avoid dislodging the hydrogel coating from the implant during surgery.
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Fig. 4.1: Two – electrode cochlear implant used in the study.
Implants were constructed in – house using Pt/Ir wire. The ball electrode was
insulated with polyimide tubing and the helix electrode was wrapped around the
polyimide. Silastic insulated the space between the two electrodes. For treatment
groups that received hydrogel coated implants, the implant was dipped in
alginate hydrogel that formed a coating around both electrodes (top panel). This
coated could be dehydrated (middle panel), to allow a cochlear implantation
similar to an uncoated implant (bottom panel), and the coating swelled once






Eleven male pigmented guinea pigs (Elm Hill, Chelmsford, Mass, USA)
were used in this study, and weights ranged from 400 – 600 g at time of
implantation. Pure tone auditory brainstem responses were recorded pre – and
post – deafening to ensure normal hearing levels and thoroughness of the
deafening procedure. This study was performed in accordance with National
Institutes of Health Guidelines (Guide for the Care and Use of Laboratory
Animals, 1996). The University Committee on the Use and Care of Animals at the
University of Michigan approved the experimental protocols. Veterinary care and
animal husbandry were provided by the Unit for Laboratory Animal Medicine, in
facilities certified by the Association for Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC, Intl).
Deafening and implantation
Animals were systemically deafened using a combination of kanamycin
(400 mg/kg, SQ), and ethacrynic acid (40 mg/kg, IV, two hours following
kanamycin) one week prior to implantation. Animals were given a ketamine (40
mg/kg) and xylazine (10 mg/kg) mix (IM) for general anesthesia and lidocaine
was used as a local anesthetic. For cochlear implantation, an incision was made
down the midline of the head and muscle and connective tissue were gently
pushed apart to reveal the skull. Three screws were placed in the skull to form a
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triangle around bregma and these screws held the head of a restraining bolt. The
base of the cochlear implant was connected to the restraining bolt to secure the
implant to the animal’s head. An incision was made in an arc caudal to the pinna
of the ear to be implanted (left ear for all animals) and the underlying muscle and
tissue were gently pushed back to reveal the bulla. A small hole was made in the
bulla with the tip of a scalpel blade and a small cochleostomy was made just
apical to the round window to expose the scala tympani. Implants were inserted
approximately one – third to one – half of the way into the basal turn of the
cochlea. Carboxylate cement was applied to the hole in the bulla to seal the
middle ear space and secure the position of the implant. The skin incision was
sutured in two layers and the animal was given warm subcutaneous fluids and
allowed to recover.
Neurofilament assessment
Four weeks post – implantation, animals were deeply anesthetized and
decapitated. Both temporal bones were removed and processed as previously
described (Chapter 3). Briefly, the temporal bone was trimmed to reveal the
cochlea and the implant remained immobile by the carboxylate cement attaching
it to the temporal bone. With the implant still in place, each cochlea received a
local perfusion of 4 % paraformaldehyde and allowed to soak in 4 %
paraformaldehyde overnight. The wall of the basal turn of the cochlea was
carefully trimmed using a bone drill and diamond burrs and/or forceps to reveal
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the implant in place within the scala tympani. Immunohistochemistry was
performed using neurofilament 160kD (1:100) as the primary antibody and FITC
as the second antibody (1:200). Specimens were viewed under a Leica MXFL III
stereo fluorescence microscope (Leica, Eaton, PA).
4.3. Results
Stereoscopic view
Stereoscopic images from one animal from each of the three treatment
groups are shown in Fig. 4.2 (hydrogel + BDNF), Fig. 4.3 (hydrogel – only), and
Fig. 4.4 (bare). The images on the left (A) are under bright light for orientation
purposes, and the images on the right (B) are under fluorescent light and are
magnified views of the basal scala tympani. Neurofilament – labeled processes
(white arrows) were visible within the scala tympani in the hydrogel + BDNF and
hydrogel – only groups. These fibers were located in various locations within the
scala tympani, including near the basilar membrane (Fig. 4.2B) and near the
outer scala tympani wall (Fig. 4.3B). There was no observed consistency of fiber
location within groups. There were no neurofilament – positive processes seen in
control cochleae.
In addition to the neurofilament – positive processes seen near the basilar
membrane and the scala tympani wall, fibers were also seen in close vicinity to
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the cochlear implant. A higher magnification image of the ball electrode from an
animal in the hydrogel + BDNF group is shown in Fig. 4.5. Individual fluorescent
fibers are clearly visible within 50 !m of the ball electrode, within the hydrogel
complex. There were fluorescing fibers also seen in different focal planes,
indicating more neurites throughout the hydrogel, surrounding the ball electrode.
Fig. 4.2: Neurofilament positive fibers within the scala tympani of a cochlea implanted with a hydrogel and BDNF
coated implant.
(A) shows the entire cochlea under bright light and (B) shows a magnified view of the basal turn of the cochlea under
fluorescent light. The cochlear implant (b = ball electrode) and neurofilament – labeled fibers (white arrows) are both
visible within the scala tympani. Scale bar in A = 1mm, scale bar in B = 500!m,





Fig. 4.3: Neurofilament positive fibers within the scala tympani of a cochlea implanted with a hydrogel – only
coated implant.
(A) shows the entire cochlea under bright light and (B) shows a magnified view of the basal turn of the cochlea under
fluorescent light. The cochlear implant (b = ball electrode) and neurofilament – labeled fibers (white arrows) are both
visible within the scala tympani. Scale bar in A = 1mm, scale bar in B = 500!m, bm = basilar membrane.
8
6
Fig. 4.4: Neurofilament positive fibers within the scala tympani of a cochlea implanted with an uncoated implant.
(A) shows the entire cochlea under bright light and (B) shows a magnified view of the basal turn of the cochlea under
fluorescent light. The cochlear implant (b = ball electrode, h = helix electrode) is visible within the scala tympani, but no
neurofilament – positive processes were evident. Scale bar in A = 1mm, scale bar in B = 500!m,




Fig. 4.5: Magnified view of the ball electrode within the scala tympani.
(A) shows the ball electrode from an animal that received a hydrogel and BDNF
coated implant, and (A’) shows a magnification view of the region highlighted in
blue. Several neurofilament – labeled processes are visible in the immediate
vicinity of the electrode. Other fibers in lower focal planes are visible as a glow,
also close to the electrode.
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The number of animals who showed neurofilament – labeled processes
within the scala tympani is quantified in Fig. 4.6. Three out of four animals (75 %)
in both the hydrogel + BDNF and hydrogel – only groups showed fluorescing
neurites, and no animals in the bare implant group showed fluorescing neurites
within the scala tympani. All animals showed fluorescing auditory nerve as it
exited the temporal bone, which verified successful staining (see Chapter 3 for
details on central auditory nerve fluorescence).
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Fig. 4.6:  Percent of cochleae within each treatment group with
neurofilament – positive fibers within the scala tympani.
Three out four cochleae in both the hydrogel + BDNF and hydrogel – only groups
showed neurofilament – labeled processes within the scala tympani. There were
no processes seen in the cochleae from the bare group.
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4.4. Discussion
We found that the application of an RGD – modified hydrogel to the
cochlear implant could create an environment within the cochlea that supported
and attracted neurite growth near the cochlear implant. The introduction of BDNF
to gel coating did not improve neurite growth compared to hydrogel alone.
Previous studies have shown that the regeneration and growth of auditory
nerve peripheral processes is possible. However, these studies have looked at
the processes in their normal locations within the cochlea, the osseous spiral
lamina and the habenula (Wise et al., 2005; Glueckert et al., 2008). Spontaneous
neurite growth has shown that fibers can extend briefly into the scala tympani
(Leake and Hradek, 1988; Staecker et al., 1996), but what we show here is
significant neurite growth over several hundred micrometers within a fluid – filled
space with the aid of a hydrogel scaffold. We saw this growth with hydrogel
coatings that both did and did not contain BDNF, indicating that the addition of a
growth factor was not necessary to attract neurites. The hydrogel used in this
study was customized to include an RGD motif, which could have provided
attractant cues that non – modified hydrogel would not have.
The type of neurite growth seen here could be quite beneficial for cochlear
implant stimulation. Stimulating the nerve endings could lower the current
required to reach threshold (Stypulkowski and van den Honert, 1984), which
could lead to decreased channel interaction and improved speech – processing
strategies. In addition, the hydrogel coating could improve the biocompatibility of
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the cochlear implant by providing a physical buffer between the metal of the
implant and the soft tissue of the cochlea and the delicate neurites.
The nature of the stereoscopic images in this study does not allow
accurate quantification of the number of neurites within the scala tympani (see
Chapter 3). The three – dimensional view leads to several different focal planes
with fluorescent fibers in one image, as seen in Fig. 4.5. However, we
demonstrate in this study that a hydrogel can attract and maintain (up to four
weeks) neurite survival in fluid – filled space, over a distance of several hundred
micrometers. Several hydrogels are already approved for clinical use in a number
of biological systems, particularly for wound healing and tissue regeneration
(Zimmermann et al., 2000). This study indicates the potential for hydrogel
coatings to facilitate and improve CI performance. The growth of neurofilament –
labeled processes within the scala tympani could improve the perception of
sound from the CI if these fibers are functional and can be stimulated. The
decrease in distance between the nerve and the electrode could decrease
current levels, cause less cellular damage and consume less battery power.
Future work should address the function of these nerves if these coating
materials are to be of benefit to cochlear implant patients.
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Chapter 5
The effect of PEDOT on cochlear implants electrophysiological thresholds
and impedances in vivo
5.1. Introduction
Cochlear implants (CIs) stimulate the auditory nerve and provide hearing
to people with severe to profound hearing loss. In the undamaged cochlea,
sound is processed by sensory hair cells, which initiate action potentials within
the auditory nerve. For many CI patients, the hair cells are missing or
degenerated to a non – functional level and thus acoustic hearing is lost. CIs
provide electrical hearing through bypassing the function of these lost hair cells
and initiating action potentials at the level of the primary ganglion cells of the
auditory nerve (spiral ganglion cells, SGCs). While current implant models
function well and can provide hearing where there once was none, there is room
for improvement. In particular, many CI users have difficulty understanding
complex sounds, such as speech with background noise and music.
The location of the CI is unusual for neural prostheses and presents a
challenge for biomedical technologies. Most implantable prostheses are placed in
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direct contact with the tissue or neural structures that are stimulated. However,
CIs are placed into the scala tympani, one of the fluid – filled spaces of the
cochlea, and at a distance of up to 1 mm from the target of electrical stimulation,
SGCs. The stimulation from the implant must pass through perilymph, bone, and
soft tissue before reaching SGCs, all of which can affect impedance and current
levels. In addition, the exact location of the implant within the scala tympani can
vary between the lateral wall and the modiolus. The distance from the nerve and
the implant affects the physiological thresholds to stimulation (Shepherd et al.,
1993; Cohen et al., 2005; Briaire and Frijns, 2006). Reduced distance between
the nerve and the electrodes can decrease thresholds and the spatial spread of
excitation, potentially leading to more independent channels of stimulation and
more complex speech processing strategies. Advancements in the processing of
sound could improve the quality of hearing for CI users.
Conducting polymers, including polyaniline, polpyrrole and poly(3, 4 –
ethylenedioxythiophene) (PEDOT) have been used in recent years in neural
probes and prostheses as a means of improving the electrode – tissue interface
(Green et al., 2008). These polymers create a fibrous coating around individual
electrodes that substantially increases the surface area of the electrode. The
application of conducting polymers on both stimulating and recording electrodes
leads to improved signal – to – noise ratio, decreased impedances, reduced scar
tissue formation, and improved charge transport (Cui et al., 2001; Ludwig et al.,
2006). For cochlear implants, conducting polymers offer the ability to manipulate
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the environment immediately surrounding the implant in ways that could improve
electric hearing.
Hydrogels have also been used extensively in clinical and basic research
to aid in tissue and organ regeneration and engineering (Coviello et al., 2006;
Mano et al., 2007). Hydrogels are mostly water – based materials with cross –
linked polymer chains that can both swell and dehydrate. These gels imitate an
extracellular matrix by providing scaffolds to support neuronal and tissue growth
and are porous enough to allow drug delivery. Hydrogels are highly
biocompatible, as they can be made from natural materials, such as
polysaccharides, and can degrade over time. Alginate is one polysaccharide
used to form hydrogels that has been used in several biological systems. In the
cochlea, alginate hydrogels have been used to effective deliver neurotrophic
factors and transfected cells into the cochlea (Endo et al., 2005; Noushi et al.,
2005; Rejali et al., 2007).
This study addresses the effects of a combination of a conducting polymer
(PEDOT) and hydrogel coating on cochlear implant stimulation. When PEDOT is
grown galvanostatically in the presence of a hydrogel, an outgrowth of the
polymer through the gel matrix is achieved, effectively extending the reach of the
electrode (Kim et al., 2004). This extension of the electrodes will decrease the
initial distance between the nerve and the electrode. The hydrogel also provides
a stabilizing force for the implant, as the gel encircles the implant and will extend
to the walls of the scala tympani and center the implant within that space. This
could reduce variability in distance from the implant and improve the fidelity of
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the stimulation. The combination of conducting polymer and hydrogels to form a
cochlear implant coating should enhance their individual effects on implant
performance. The current study tested the in vivo effects of this combined
cochlear implant coating on electrophysiological thresholds to cochlear implant
stimulation and on impedances between implant electrodes.
5.2. Methods
Implant Construction and Coating
Cochlear implants were made in – house as previously described
(Chapter 3). Implants received a hydrogel + PEDOT coating (labeled GelDOT), a
PEDOT coating (labeled PEDOT), or no coating at all (labeled Bare). PEDOT
was first electrochemically deposited on the two electrodes of the implant as
previously described (Cui et al., 2001). The solution used for deposition was a
0.1 % EDOT / 0.2 % polystyrene sulfonate (PSS) in distilled water. Hydrogel
coatings were applied by dipping the implant into two solutions a 1 % RDG –
alginate in PBS (Rowley et al., 1999) and 2 % CaCl2 in PBS (Kim et al., 2004).
Implants were dipped in the gel solutions four times to build up a coating on the
implant that was approximately 50 !m thick. After hydrogel coating, the implants
were placed in a 0.1 % EDOT / 0.2 % PSS / 2 % CaCl2 / PBS solution for
additional deposition, which formed the PEDOT – PSS extensions through the
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gel. GelDOT coated implants were also soaked in 400 ng/mL of brain – derived
neurotrophic factor (BDNF) as part of a separate experiment. Implants were
sterilized for surgery using ethylene oxide, and the hydrogel coated implants
remained dehydrated until implantation into the cochlea.
Subjects
Twelve male pigmented guinea pigs (Elm Hill, Chelmsford, Mass, USA)
were used in this study. Weights ranged from 400 – 600 g at the time of
implantation. Animals were ototoxically deafened so that hair cell function would
not interfere with the electrophysiological threshold recordings. Pure tone
auditory brainstem responses were recorded pre – and post – deafening to
ensure normal hearing levels and thoroughness of the deafening procedure. This
study was performed in accordance with National Institutes of Health Guidelines
(Guide for the Care and Use of Laboratory Animals, 1996). The University
Committee on the Use and Care of Animals at the University of Michigan
approved the experimental protocols. Veterinary care and animal husbandry
were provided by the Unit for Laboratory Animal Medicine, in facilities certified by




Animals were systemically deafened using a combination of kanamycin
(400 mg/kg, SQ), and ethacrynic acid (40 mg/kg, IV, 2 hours following
kanamycin) one week prior to implantation. Animals were given a ketamine (40
mg/kg) and xylazine (10 mg/kg) mix (IM) for general anesthesia and lidocaine
was used as a local anesthetic.
For cochlear implantation, an incision was made down the midline of the
head and muscle and connective tissue were gently pushed apart to reveal the
skull. Six screws were placed in the skull; three for electrically – evoked auditory
brainstem response recordings and three screws that formed a triangle around
bregma. These screws held the head of a restraining bolt, which connected to
the base pedestal of the implant. The screws for electrically – evoked auditory
brainstem response recordings were located 2 cm anterior to bregma, 1 cm
lateral of bregma on the implanted side, and 1 cm posterior to bregma.
An incision was made in an arc caudal to the pinna of the ear to be
implanted (left ear for all animals) and the underlying muscle and tissue were
gently pushed back to reveal the bulla. A small hole was made in the bulla with
the tip of a scalpel blade and a small cochleostomy was made below the lip of
the round window to expose the scala tympani. Implants were inserted
approximately one – third to one – half of the way into the basal turn of the
cochlea (2 – 3 mm). Carboxylate cement was applied to the hole in the bulla to
seal the middle ear space and secure the position of the implant. A ground
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electrode (500 !m ball electrode, Pt – Ir) was placed in the post – auricular
muscle. The skin incision was sutured in two layers and the animal was given
warm subcutaneous fluids and allowed to recover.
Impedances
The impedance between the ball and helix electrodes, the ball and ground
electrodes, and the helix and ground electrodes, was measured following
implantation. Values were obtained several times a week and an average value
per week was used for analyses. Impedances were measured using a 1 !A rms,
1 kHz sinusoid wave from an in – house constructed impedance meter.
Electrically – evoked auditory brainstem response
Electrically – evoked auditory brainstem responses (EABRs) were
recorded as previously described (Chapter 2), under general anesthesia once a
week for four weeks beginning one week post – implantation. Electrical stimuli
were 50 !s phase duration monophasic alternating polarity square pulses. Neural
activity was recorded using alligator clips attached to screws that were placed in
the skull. One bipolar (ball – helix electrode) and two monopolar (ball – ground
and helix – ground) electrode configurations were tested. EABR threshold was




Impedances averaged over the entire testing period were significantly
lower for both GelDOT and PEDOT than for the Bare group (Fig. 5.1). This
difference was seen in both monopolar and bipolar configurations and was
evident within the first week of implantation (one – way ANOVA for each
configuration, p < 0.05). There were no differences between the GelDOT and
PEDOT groups in any configuration.
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Fig. 5.1: Average impedance values at 1kHz
Weekly impedance values for three electrode configurations were averaged over
the four week testing period and compared between groups. GelDOT/BDNF and
PEDOT coated implants had significantly lower impedances than the uncoated
group in all configurations, and there were no differences between the GelDOT
and PEDOT groups. One – way ANOVA was performed on each electrode pair,
(*) indicates p < 0.05.
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Over time, impedances increased for all groups, as is typical for chronic
implantation. However, the rate of increase varied between groups (Fig. 5.2). For
the bipolar (ball – helix) configuration, repeated measures two – way ANOVA
revealed a significant effect of both group and time (p = 0.01 and p < 0.01
respectively) but no interaction between group and time (p = 0.07). This indicates
that there were significant changes within groups over time, but that the groups
remained distinct from each other. There was a statistically significant difference
between thresholds at 1 and 2 weeks post – implantation for the Bare group. A
significant difference was not seen at these times points for the PEDOT and
GelDOT groups. Instead, the difference in thresholds was significant between 1
and 3 weeks post – implantation in the PEDOT group and 1 and 4 weeks post –
implantation in the GelDOT group. Similar patterns for all groups and time points
were seen in both of the monopolar configurations.
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Fig. 5.2: Impedance values averaged over time for the bipolar (ball – helix)
electrode configuration.
Data represent weekly averages per group +/ –  one standard deviation. A
repeated – measures two – way ANOVA revealed a significant effect of group
and time but no interaction between groups. The impedance between
GelDOT/BDNF and PEDOT coated electrodes was initially lower than the
impedance between bare electrodes, and the increase in impedance was not as
steep as the increase with bare electrodes.
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EABR thresholds
There was a trend towards lower EABR thresholds in the bipolar
configuration, averaged over four weeks, for the Bare group than either the
GelDOT and PEDOT groups, but this was not a statistically significant difference
(one – way ANOVA, p = 0.07) (Fig. 5.3). There were no observable or statistical
differences in either of the monopolar configurations.
There were no differences seen between groups in thresholds over time.
Fig. 5.4 represents EABR thresholds for the ball – ground monopolar electrode
configuration, separated into weekly intervals. There was a significant effect of
time (p < 0.01) but not group (p = 0.51) and no interaction between group and
time. These data indicate that all groups showed similar changes in thresholds
over time, which was a slight decrease from initial thresholds. A similar pattern
was seen in the second monopolar configuration (helix – ground). The bipolar
configuration did not show an effect of time or group, and all three groups had
thresholds that were stable over time but not statistically significant from each
other.
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Fig. 5.3: Average EABR Thresholds for each electrode configuration.
Weekly EABR thresholds were averaged per group and one – way ANOVA was
performed for each configuration. No differences were found in any of the three
electrode configurations tested.
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Fig. 5.4: EABR thresholds in a monopolar configuration over time.
Weekly thresholds were averaged per group and a two – way repeated
measures ANOVA was performed to determine changes over time. There was no
interaction between group and time, but there was an effect of time.
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5.4. Discussion
The PEDOT and GelDOT coatings applied to the cochlear implant prior to
implantation affected long – term in vivo impedance measures but did not affect
electrophysiological thresholds. The greatest effect of the coatings on
impedances was not seen in averages over time, but rather in the changes over
time. This may be reflective of how each element of the coating affects either the
electrical signal itself or the tissue response to cochlear implantation and
electrical stimulation.
Impedance values are a function of both the characteristics of the
electrodes and the status of the environment immediately surrounding the
electrodes. The PEDOT coating on the electrodes created greater surface area;
this most likely accounts for the overall decrease in impedance values with both
the GelDOT group and the PEDOT group. This has been shown in cortical
recordings and in vitro stimulation, but this is first evidence that the addition of a
conducting polymer on the electrodes of a chronic cochlear implant can improve
impedances in vivo. In the cochlea, increases in the impedance at frequencies
such as the one used here (1 kHz), soon after implantation, can be attributed to
changes in the immediate vicinity of the electrode (Duan et al., 2004). The
differences between the treatment groups seen here in the rate of change are
therefore most likely due to differences in the electrode – cochlea interface
caused by the coating. The GelDOT group had a slower rate of impedance
increases than the PEDOT group, which in turn had a slower rate of impedance
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increases than the Bare group. The slower rate of increasing impedances over
time for both the GelDOT and PEDOT groups may indicate that the conducting
polymer slowed or reduced the intrascalar tissue growth that often accompanies
cochlear implantation, and that the addition of hydrogel coating further enhanced
this effect.
Although we saw a decrease in impedances with the PEDOT and GelDOT
coatings, we did not see a corresponding decrease in EABR thresholds. Previous
research indicates that lower physiological thresholds are correlated with
improved auditory nerve survival (Shepherd et al., 2005). The lack of a difference
in EABR thresholds seen here may therefore be an indication that the implant
coatings did not affect the survival or the function of the auditory nerve or
pathway, but instead merely changed the properties of the implant itself. The
tissue – implant interface is a critical facet of research focused on improving
cochlear implant function, and it is important to address both the tissue and
implant aspects of the interface. While the PEDOT and GelDOT coatings may
not have changed the cochlear environment in a significant manner, they did
improve the stimulation from implant, and that may have significant effects on the
perception processing of electrical stimulation.
The combination of a PEDOT and alginate hydrogel around the cochlear
implant in vivo has great potential to improve electric hearing. The lower
impedances and the slower rate of impedance increases over time in the
GelDOT & PEDOT coatings could be important to future implant design and
construction. Lower impedances could lead to lower voltage requirements,
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increasing battery life and allowing the use of more complex speech processing
software. A shallower rate of impedances increases over time could prohibit
some of the issues that arise with high impedances, including signal compliance
and compromised fidelity of the stimulation signal. Future physiological testing is
required to fully characterize the effects of this coating on the processing of
cochlear implant signals, as threshold levels alone may not be a sensitive
enough measure. Although further refinements are necessary to fully
characterize the clinical benefits of such a coating, this study demonstrates the





This dissertation presents several methods for improving auditory nerve
survival following hair cell loss that are relevant to cochlear implant function. In
an animal model of sensorineural hearing loss, these methods improved spiral
ganglion cell survival, attracted peripheral processes growth into the scala
tympani, lowered psychophysical detection threshold to cochlear implant
stimulation, lowered electrophysiological thresholds to cochlear implant
stimulation, and reduced impedances between implant electrodes. Any of these
changes individually would be of interest to cochlear implant research, but the
combination provides novel, exciting and clinically relevant data. The studies
included in this dissertation employed molecular, cellular, physiological, and
behavioral level metrics that provide a more complete understanding of the
effects of the techniques used.
6.1. Adenoviral mediated up – regulation of BDNF
In the first study, an adenoviral construct containing a gene insert for the
growth factor BDNF promoted spiral ganglion cell survival 80 days post –
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inoculation. This inoculation also led to lower EABR thresholds and lower
psychophysical detection thresholds with focused electrical stimulation. Spiral
ganglion cell survival was highly correlated with EABR thresholds, but not
psychophysical detection thresholds. This study showed an effect of a molecular
level change on a systems level response and highlighted the need for several
modes of cochlear implant functional assessment.
Ad.BDNF was inoculated into the cochlea at the time of implantation, four
days after ototoxic lesioning. An increase in BDNF concentration in perilymph
was seen between seven and fourteen days following Ad.BDNF inoculation
(Figure 2.2). This time course allowed at least eleven and up to eighteen days of
neural degeneration between initial trauma and potential effects of BDNF
protection. Aminoglycoside – induced hair cell loss is seen within four days
following introduction into the cochlea (Kim and Raphael, 2007), and significant
ganglion cell degeneration can be seen within two weeks of ototoxic deafening
(Webster and Webster, 1981). This suggests considerable cell body
degeneration could have occurred before BDNF production was increased
significantly. The timing of these events suggests that the Ad.BDNF treatment
may have not only preserved some SGCs but also promoted growth of new
neurons. The idea that growth factors can regenerate SGCs is supported by
other studies that show SGC survival following a delay between deafening and
growth factor treatment (Gillespie et al., 2004; Yamagata et al., 2004) as well as
studies that show an increase in SGC density above normal levels after growth
factor treatment (Shepherd et al., 2005; Glueckert et al., 2008).
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Neuronal regeneration may also be indicated by the changes in EABR
thresholds over time (Fig 2.6). The control group’s thresholds increased over
time, which may be attributable to a degeneration of the auditory nerve over time.
Likewise, the decrease in EABR thresholds in the Ad.BDNF group over time may
by attributable to a regeneration of the nerve. A similar trend was seen in a study
by Shinohara et al. (2002), where EABR thresholds declined over time in a
animal group that received growth factor treatment. In this study, growth factors
were introduced to the cochlear continuously over the experimental timeframe
using an osmotic pump; in the current study a single Ad.BDNF inoculation
produced similar results. A separate longitudinal study assessing SGC density at
different time points could further elucidate this result.
It is possible that the changes seen in EABR thresholds were not related
simply to SGC density, but rather SGC function. Although not assessed in this
study, growth of peripheral processes in addition to cell bodies following
Ad.BDNF inoculation is feasible. These processes may have facilitated the
transmission of electrical stimulation, particularly if the processes were
myelinated. Future studies could include more detailed histological examination
of the osseous spiral lamina and Rosenthal’s canal, as well as the myelination of
the central auditory nerve.
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6.2. Neurite growth within the scala tympani
In the second study, a hydrogel coating promoted neurite growth within
the scala tympani near a CI in vivo. Neurite growth was seen within the scala
tympani of cochleae that received a hydrogel coated implant both with and
without BDNF. This indicates that the presence of a scaffold within the scala
tympani was sufficient to support growth, without a chemoattractant source.
While previous research has shown that auditory nerve processes can
regenerate following hair cell trauma, (Cho et al., 1998; Wise et al., 2005;
Glueckert et al., 2008), anatomical assessments have been restricted to the
osseous spiral lamina and habenula; that is, the normal, expected sites of these
processes. This study was able to show fiber growth in the fluid – filled space of
the scala tympani, a distance of several hundred micrometers from the normal
location. Growth was seen within the hydrogel complex in various regions of the
scala tympani, including the direct vicinity of the cochlear implant. The hydrogel
coating promoted significant neurite growth, as nine out of twelve animals that
received a hydrogel – coated implant showed some neurofilament – labeled
processes within the scala tympani.
The hydrogel used in this study was not a simple alginate gel, but rather
was modified prior to use to include an arginine – glycine – aspartic acid (RGD)
motif. RGD is an integrin – binding site for a vast number of extracellular matrix
ligands, which effectively promotes cell adhesion (Ruoslahti, 1996). This
sequence has been coupled to the polysaccharide chains of the alginate gel, and
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has been shown to promote muscle and bone tissue growth (Rowley et al., 1999;
Alsberg et al., 2003). This modification may be vital to the neuronal growth that
we have seen in this study, by providing a source of support for neurite ingrowth
within the hydrogel. This modification may also explain the neurite growth seen
without BDNF, because the RGD served as an attractant when BDNF was not
available.
With the immunolabeling system used in this study, we cannot be sure
that the fibers seen within the scala tympani are in fact auditory nerve fibers.
Neurofilament is found in all nerves and it is possible, although unlikely due to
the relative isolation of the cochlea, that the fibers seen here came from a source
other than the auditory nerve. We also do not know if these fibers are afferent or
efferent, and this will be a major topic to address if this type of neural
regeneration is to be of use to cochlear implant function. These issues, however,
do not negate the exciting results that we have developed a method to attract
nerve fibers to grow through cochlear fluids over a distance of several hundreds
micrometers toward a cochlear implant in vivo.
The concentration of BDNF within the cochlea over time should also be
assessed in future studies. Our hydrogel coated implants were soaked in 10 µL
of 400 ng/mL BDNF, which is a relatively high concentration of the growth factor.
Neurotrophins, including BDNF and NT – 3, are effective at promoting spiral
ganglion cell survival when introduced into the cochlea in lower concentrations
[i.e. 50 ng/mL, (Miller et al., 1997; Wise et al., 2005)]. However, the supply of low
concentration growth factors is continually replenished if introduced through
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osmotic pumps, as in the above studies. The passive release of growth factors
from the hydrogel – coated implants in the current study provided only one non –
renewable source of growth factors; we increased the concentration to
compensate for this. Interestingly, when neurite regrowth was seen in the scala
tympani by Staecker et. al. (1996), a growth factor concentration of 1 mg/ml was
used. In comparison to this study, the current results show significant neurite
growth within the scala tympani using four orders of magnitude lower
concentration of BDNF.
A novel histological method was developed in the course of this study to
determine the spatial relationship between neurites and a cochlear implant in
situ. This technique was sensitive enough to visualize individual neurites, yet
broad enough to view the implant and the cochlea around it. The development of
this technique was crucial to the results of this study. Our goal was to determine
if we could induce neurite growth near the cochlear implant, which necessitated
viewing both the implant and the neurites simultaneously. No other established
technique allowed us this opportunity, and therefore a portion of this dissertation
was dedicated to the development of this technique. This method is not limited to
this study, but could be easily applied to future research involving intra – scalar
morphological changes induced by or directly related to cochlear implants.
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6.3. PEDOT coating reduces in vivo impedances
In the third study, a conducting polymer/hydrogel coating on the cochlear
implant reduced both bipolar and monopolar impedances but did not affect EABR
thresholds. The conducting polymer, PEDOT, has previously been used in
recording electrodes (Ludwig et al., 2006), but this is the first published data
showing the effect of PEDOT on stimulating electrodes. A reduction of in vivo
impedances is important to cochlear implant performance for several reasons.
With low impedances, a lower voltage is required to produce the same current
level needed to activate neurons, and a lower voltage could lead to lower battery
usage. Battery life and replacement is an issue with implantable prostheses in
general. A reduction in the need to replace batteries would make life simpler for
implant users and a decrease in the battery consumption for stimulation could set
aside more battery power for speech processing software. Increased speech
processing strategies are theoretically available, but not yet utilized because of
their high battery demands, but decreasing impedances could indirectly aid this
process.
A reduction in impedances is also important for long – term implant
characteristics because high impedance values affect implant compliance and
can degrade the fidelity of the electrical signal. This can disrupt or distort the
perception of sound for cochlear implant users. Impedances typically increase
with time following implantation, as demonstrated by the control group in Fig. 5.2.
The PEDOT coating slowed the rate of impedance increases over time,
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potentially allowing longer implantation times. Future longitudinal studies could
further reveal the effects of this coating on in vivo impedance changes following
implantation. This study demonstrated that the PEDOT and/or GelDOT coating
made the implant more biocompatible (as evidenced by the decrease in
impedances) yet did not attenuate the electric hearing process (as evidenced by
the lack of difference in EABR thresholds).
6.4. Summary
Both the adenoviral inoculation and the hydrogel/conducting polymer
coating offer long – term, highly effective means of delivering growth factors to
the cochlea and promoting survival and regeneration of the auditory nerve. This
is an important consideration for cochlear implant work because the stimulation
from the implant is dependent on a functional auditory nerve, yet the nerve is
susceptible to degeneration over time. Although the studies in this dissertation
presented growth factor treatment at the time of implantation, both inoculation
and hydrogel insertion to the cochlea prior to implantation are also feasible. This
approach to growth factor treatment may support nerve survival until implantation
can occur.
The ultimate goal of this and other research is to improve the processing
of complex sounds so that cochlear implant users receive more complete
auditory perception. The increase in SGC density, directed growth of nerve fibers
to make contact with a cochlear implant, and reduced in vivo impedances
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present several potential physiological and perceptual benefits to cochlear
implant users. The results from these three studies could lead to a lower level of
current required to stimulate the nerve. Lower current levels could decrease the
spread of excitation from each electrode of the implant, allowing more
independent channels of stimulation. Of course, lowering current levels is just
one way to improve cochlear implant function, and will likely need to be
combined with other advances in hardware and software engineering to provide
more complete perception of sound. Future morphological, physiological,
psychophysical testing is required to fully develop the clinical applicability of the
treatments described in this dissertation. However, the data presented in these
studies provide evidence that changing the morphology of the cochlea to make it






Color Images from Chapter 3
Visualization of spiral ganglion neurites within the scala tympani with a
cochlear implant in situ
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Fig. 3.1: Basal cochlear dissection with implant in place.
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Fig. 3.2: Neurofilament staining of the central auditory nerve.
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Fig. 3.3: Neurofilament staining within the cochlea.
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Fig. 3.4: Examples of neurofilament – labeling within the cochlea.
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Appendix B
Color Images from Chapter 4
Cochlear implant hydrogel coating promotes auditory nerve fiber growth
within the scala tympani in direct vicinity of implant
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